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ABSTRACT
Quinn, Colin Quinn. Effects of Exercise Training and Doxorubicin on Myogenic
Regulatory Factors. Published Doctoral Dissertation, University of Northern
Colorado, 2015.
Doxorubicin (DOX) is a widely used anthracycline antibiotic used to treat a
number of hematological and solid tumor cancers. Dosage; however, is limited due to its
toxic effects in healthy tissues. Negative consequences include myotoxicity in skeletal
muscle, which may limit mobility and activities of daily living. The capacity for skeletal
muscular regeneration relies heavily of the activity of myogenic regulatory factor (MRF)
proteins. In vitro experiments with DOX depress expression of MRFs but in vivo
treatment may elicit different responses. Endurance exercise has been shown to elevate
MRF expression, and may preserve MRFs following in vivo DOX-treatment.
Purpose: To determine the effect of short-term endurance training and acute DOX
administration of skeletal muscle force production and fatigue resistance, levels of lipid
peroxidation, and expression of MRFs. Methods: Ten week old male Sprague-Dawley
rats were randomly assigned to one of four groups: sedentary + saline (SED-SAL), SEDDOX, endurance exercise training + saline (EXER-SAL), or EXER-DOX. Animals
remained sedentary or performed treadmill training for two weeks. Twenty four hours
after the activity period, animals were injected with a bolus 15 mg/kg i.p. injection of
DOX or SAL. Twenty four hours after injection, soleus (SOL) and extensor digitorum
longus (EDL) skeletal muscles were removed for ex vivo function measures. Analyses of
lipid peroxidation as malondialdehyde and 4-hydroxyalkenals (MDA + 4-HAE) and
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Western blotting for concentration for MRFs (Myf5, MyoD, myogenin, Mrf4) were
performed on contralateral muscles.
Results: Endurance exercise significantly elevated Myf5 and Mrf4 in the SOL (p<0.05).
No significant differences existed in MRF expression levels in the EDL. No significant
muscle force production or fatigue resistance differences were identified due to drug or
activity treatment. MDA + 4-HAE was higher in the SOL of SAL animals (p<0.05) and
EDL of EXER animals (p<0.05). Conclusion: Short-term endurance exercise effectively
elevated Myf5 and Mrf4 in slow, oxidative muscle after acute DOX treatment. Endurance
exercise prior to chemotherapy may augment skeletal muscles’ regenerative capacity
following treatment, when loss of muscle mass is common.
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CHAPTER I
INTRODUCTION
Background
Muscle weakness and subsequent deterioration in activities of daily living are
common side effects of chemotherapy treatments prescribed to cancer patients (Bonifati
et al., 2000; Burckart, Beca, Urban, & Sheffield-Moore, 2010; Knobel et al., 2001). The
commonly used anthracycline antibiotic, doxorubicin (DOX; trade name: Adriamycin®)
has been shown to cause severe to fatal consequences associated with its cardiotoxic
nature. Free radicals formed by iron-catalyzed reactions are implicated in nuclear and
mitochondrial damage inducing cell death (Bagchi, Bagchi, Hassoun, Kelly, & Stohs,
1995; DeAtley et al., 1999; Rapozzi et al., 1998; Stathopoulos et al., 1997). Much of the
existing literature surrounding DOX-induced injury focuses on effects seen in the heart.
More recently, research has elucidated serious skeletal muscle harm, decreasing muscle
size and function in response to DOX exposure (Doroshow, Tallent, & Schechter, 1985;
Gilliam et al., 2009; Gilliam et al., 2013; Gilliam, Moylan, Callahan, Sumandea, & Reid,
2011). Previous research has demonstrated the beneficial influence of endurance exercise
preconditioning in mitigating the negative cardio- and myotoxic consequences of DOX
treatment (Ascensão, Oliveira, & Magalhães, 2012; Chicco, Schneider, & Hayward,
2006; Hayward, Lien, Jensen, Hydock, & Schneider, 2012; Hydock, Lien, Jensen,
Schneider, & Hayward, 2011b).

2
Skeletal muscle comprises a large part of the human body, responsible for posture
and locomotion. It is unique in its plasticity to alter its form following various stimuli. In
adult muscle, myogenic regulatory factors (MRFs) guide satellite cells to restore muscle
integrity in response to damage and stress, such as exercise. Activated satellite cells,
expressing primary MRFs, form myoblasts, and differentiate into myotubes in response
to secondary MRFs and reconstitute muscle fibers. The ability of skeletal muscle to repair
itself and retain structure relies heavily on functional MRF proteins.
In vitro DOX exposure has been shown to decrease the ability of myoblasts to
differentiate into myotubes (Kurabayashi, Jeyaseelan, & Kedes, 1993). Additionally,
MRF mRNA expression is compromised under the same conditions with an up-regulation
of the MRF inhibitor, Id (Kurabayashi, Jeyaseelan, & Kedes, 1994). DOX has been
shown to induce oxidative stress, leading to cellular damage and single-stranded DNA
breaks. Beyond oxidative damage, genotoxic stress attributed to DOX leads to doublestranded DNA breaks. The primary MRF, MyoD, is fundamentally involved in myoblast
DNA repair (Kobayashi, Antoccia, Tauchi, Matsuura, & Komatsu, 2004). Its presence,
along with the other MRFs, is critical for skeletal muscle regeneration following
chemotherapy treatment including DOX. Although MRF mRNA has been broadly
investigated, functional protein expression has been less examined. Functional MRF
protein may be enhanced with endurance exercise prior to drug treatments.
In a pilot study (see Appendix B), rat skeletal muscle was examined three days
following DOX or saline injections. Sedentary animals treated with DOX versus saline
injections displayed differential expressions of MRFs in soleus (SOL) and extensor
digitorum longus (EDL) muscles. Myf5 and MyoD were lower in SOL of animals
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receiving DOX, while myogenin and Mrf4 were significantly greater. Myf5 and MyoD
increased in EDL and Mrf4 decreased following DOX injections. Prior endurance
exercise training may influence the expression of MRFs in skeletal muscle. Following
endurance training, SOL of rats demonstrated elevated levels of myogenin (Siu, Donley,
Bryner, & Alway, 2004). In combination with elevated antioxidant enzymes due to shortterm aerobic exercise, increased MRF protein may effectively mitigate the skeletal
muscle dysfunction attributed to DOX treatment and enhance subsequent repairs.
Statement of Purpose
The purpose of this study was to investigate the effects of in vivo DOX
administration on skeletal muscle force production and fatigue resistance, oxidative
damage, and expression of MRFs (MyoD, Myf5, myogenin, & Mrf4). A secondary
purpose of the study was to examine if prior short-term exercise provides protection
against DOX-induced muscle dysfunction, lipid peroxidation and MRF alterations in
skeletal muscle. Whether MRF protein expression affects muscle function or is, itself,
affected by oxidative stress may be elucidated with this research. The study addressed
myogenic mechanisms associated with adult muscle regenerative capacity occurring with
DOX treatment. An additional goal of the study was to identify whether short-term
aerobic exercise intervention can be used to offset muscular dysfunction afflicting cancer
patients.
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Research Hypotheses
Specific Aim 1
The purpose of the first specific aim was to identify the effects of DOX treatment and 2week endurance training on ex vivo skeletal muscle force production and fatigue
resistance.
H1

DOX treatment will impair skeletal muscle twitch force production and
fatigue resistance when analyzed 1 day following DOX injection.

H2

Short-term endurance exercise will minimize DOX-induced myotoxic
function.

Specific Aim 2
The second specific aim was to determine oxidative stress in response to DOX and
exercise in skeletal muscles.
H3

DOX treatment will increase lipid peroxidation levels 1 day following DOX
injection.

H4

Short-term endurance exercise will minimize DOX-induced lipid
peroxidation in both SOL and EDL.

Specific Aim 3
The third specific aim was to identify the effect of short-term exercise and acute, in vivo
DOX treatment on MRF expression in hindlimb muscles.
H5

Primary MRF protein (Myf5 and MyoD) concentrations will significantly
decrease in slow, oxidative muscles (SOL) and increase in fast, glycolytic
muscles (EDL) following in vivo DOX treatment compared with control
animals.
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H6

Secondary MRF protein (myogenin and Mrf4) concentrations will
significantly increase in SOL and decrease in EDL following in vivo DOX
treatment compared with control animals.

H7

Prior endurance exercise will attenuate MRF alterations associated with DOX
treatment.
Need for Study

Skeletal muscle weakness following chemotherapy is well documented. Decreases
in activities of daily living and susceptibility to falls can have dire consequences. Recent
literature has shown time to chemotherapy can have adverse outcomes, especially with
higher graded cancers (de Melo Gagliato et al., 2014). Although research has
demonstrated chronic endurance exercise to provide a protective effect, time does not
often allow for an extended exercise-training period. DOX prescription in chemotherapy
is quite common, and patients often experience later cardiotoxicity, but patients also
exhibit skeletal muscle degeneration and dysfunction. The benefit of exercise
preconditioning has proven useful in protecting cardiac and skeletal muscles from ills
associated with DOX treatment, but time to chemotherapy may not afford such a time
until treatment. Designing a useful, short-term aerobic exercise intervention to maintain
skeletal muscle form and function may improve the adaptive capacity of muscle
following DOX treatment. Myogenic regulatory factors play an integral role in the
regeneration of adult muscle tissue, and methods to maintain their expression may afford
greater quality of life following chemotherapy. Short-term exercise preconditioning may
offer skeletal muscles the capability to combat the oxidative and genotoxic stress
associated with doxorubicin treatment.
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Table 1.1
Abbreviations
4+HAE = 4-Hydroxyalkenals

ABL = Abelson murine Leukemia

ANOVA = Analysis of Variance

Bax = Bcl-2-associated X protein

BCA = Bicinchronic Acid

bHLH = Basic Helix-Loop-Helix

C2C12 = Mouse myoblast cell line

Ca2+ = Calcium

Caspase = Cysteine-aspartic protease

CHF = Congestive Heart Failure

CO = Carbon monoxide

DDR = DNA Damage Response

DNA = Deoxyribonucleic Acid

DOX = Doxorubicin

DSB = Double-Strand Break

ECL = Enhanced Chemiluminescence

EDL = Extensor Digitorum Longus

EXER = Exercise

GPX = Glutathione Peroxidase

H2O2 = Hydrogen Peroxide

HRP = Horseradish Peroxidase

Hz = Hertz

i.p. = Intraperitoneal

Id = Inhibitor of DNA binding

K+ = = Potassium

LPO = Lipid Peroxidation

mA = Milliampere

MCK = Muscle Creatine Kinase

MDA = Malondialdehyde

MEF2 = Myocyte Enhancer Factor 2

MPC = Myogenic Progenitor Cell

MRF = Myogenic Regulatory Factor

mRNA = Messenger RNA

MyHC = Myosin Heavy Chain

Nbs1 = Nijmegen Breakage Syndrome 1 gene

O2- = Superoxide Anion

OH = Hydroxyl radical

Pax = Paired-homeobox

PUFA = Polyunsaturated Fatty Acid

PVDF = Polyvinylidene Fluoride

RIPA = Radioimmunoprecipitation Assay

RNA = Ribonucleic Acid

-

ROO = Peroxyl

ROS = Reactive Oxygen Species

SAL = Saline

SC = Satellite Cell

SDS-PAGE = Sodium Dodecyl Sulfate-

SED = Sedentary

Polyacrylamide Gel Electrophoresis
SHH = Sonic Hedghog

SOD = Superoxide Dismutase

SOL = Soleus

SR = Sarcoendoplasmic Reticulum

SSB = Single-Strand Break

TBST = Tris-Buffered Saline with Tween20

TM = Treadmill

TNF = Tumor Necrosis Factor

TOP2 = Topoisomerase II

V = Volt
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Definition of Terms
Anthracycline – Class of antibiotic used in chemotherapy derived from Streptomyces
bacterium
Antineoplastic – Preventing the growth and spread of tumors or malignant cells
Apoptosis – Process of programmed cell death, marked by morphological changes and
DNA fragmentation
Caspase – Cysteine protease involved in direction of apoptosis, necrosis, and
inflammation
Double-strand break – Condition where both strands of DNA double helix have been
individually cleaved without separation of the two strands
Doxorubicin – Bacterial antibiotic used in the treatment of various cancers
Embryogenesis – Formation and development of an embryo
Genotoxic stress – Damage to the genome of an organism as result of a genotoxin
Genotoxin – Substance capable of causing damage to cellular DNA and causing
mutations or cancer
Myogenesis – Formation and growth of muscle tissue
Oxidative stress – Damage caused to cells or tissue as result of reactive oxygen species
Redox cycling – Reactions involving the transfer of electrons, resulting in change
between reduced and oxidized states
Single-strand break – Cleavage of only one of the two strands of DNA, while both
strands remained attached to one another
Zymogen – Inactive enzyme precursor
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CHAPTER II
REVIEW OF LITERATURE
Doxorubicin
Doxorubicin (DOX; trade name: Adriamycin®) is a widely used antineoplastic
for treating both solid and hematological cancers. Clinically, DOX is administered
intravenously (i.v.) and in some cases directly into the abdomen via intraperitoneal (i.p.)
injections (Chabner, Ryan, Paz-Ares, & Garcia-Carbonero, 2001; Chu & DeVita, 2006;
Sugarbaker, 2009; Van der Speeten, Stuart, Mahteme, & Sugarbaker, 2009).
Unfortunately, DOX use is limited due to undesirable effects on cardiac muscle,
including contractile dysfunction, dilated cardiomyopathy, and congestive heart failure
(CHF) (Singal, Li, Kumar, Danelisen, & Iliskovic, 2000; Singal & Iliskovic, 1998).
Additionally, skeletal muscle dysfunction is observed following DOX administration.
DOX-induced skeletal myopathies can lead to severe respiratory and locomotor
impairments (Kavazis, Smuder, & Powers, 2014).
The proposed mechanisms behind the antineoplastic action of DOX suggest that
DOX inhibits DNA synthesis, forms free radicals, promotes lipid peroxidation, binds and
alkylates DNA, interferes with DNA separation activity, directly affects cell membranes,
initiates DNA damage via topoisomerase II, and signals apoptosis (Gewirtz, 1999;
Minotti, Menna, Salvatorelli, Cairo, & Gianni, 2004). Anthracyclines, like DOX, are
prone to generate reactive oxygen species (ROS) when mitochondrial enzymes interact
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with a quinone ring C of DOX (Figure 2.1), releasing electrons that are captured by
oxidizing agents (i.e., oxygen). Molecular oxygen is then reduced to ROS like
superoxide, hydroxyl and peroxide radicals. Elevated levels of ROS lead to lipid
peroxidation, DNA damage and cell apoptosis, arresting malignant cancer growth. These
effects, however, are not limited to cancerous cells, and healthy cells are also affected.
Because of this unwanted side effect, dosages of DOX are limited to minimize side
effects.

Quinone ring C
cycling between
oxidized and
reduced states

Figure 2.1. Structure of DOX (Minotti et al., 2004)

Reactive Oxygen Species
Oxidative stress is a condition in which the cellular balance of pro-oxidants
outweighs antioxidants. Oxidative stress primarily occurs when oxygen free radicals
accumulate within the body. Oxygen free radicals are small, diffusible molecules with an
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unpaired electron, such as hydrogen peroxide (H2O2), superoxide anion (O2-), peroxyl
(ROO-), or hydroxyl radical (OH). Accumulated oxidative damage has been shown to
induce mitochondrial damage and apoptosis, while furthering the formation of ROS
(Valko et al., 2007).
Any protein or enzymatic system, which transfers electrons, can form ROS by
donating or receiving electrons from oxygen or oxygen-derived compounds. Therefore,
ROS byproducts can be found in mitochondria, peroxisomes, cytochrome p450 reactions
and phagocytic immune responses. Flavoenzymes use NADPH as an electron source in
redox cycling. An electron is transferred from NADPH to the quinone of anthracyclines,
reducing it to a semiquinone state. The semiquinone rapidly returns to its parent state
once the electron is donated to oxygen, forming superoxide (O2-) (Gutierrez, 2000).
Following DOX administration, ROS are produced largely in the mitochondria, with
redox cycling at complex I of the electron transport chain (Minotti et al., 2004). At this
stage, DOX is converted to a semiquinone reactive, forming O2- and subsequent H2O2
and OH (Davies & Doroshow, 1986; Doroshow & Davies, 1986).
In the normal physiological environment, oxygen free radicals are produced as
part of oxidative metabolism. In addition to inducing apoptosis, ROS can signal gene
expression as second messengers. ROS production is a major regulator of signaling
pathways promoting skeletal muscle adaptations following exercise (Franco, Odom, &
Rando, 1999; Li, Chen, Li, & Reid, 2003). The levels of ROS, however, must be
maintained at homeostatic levels to allow cellular processes of muscle growth and
differentiation. Although exercise leads to a spike in oxygen free radical production,
antioxidant enzymes are increased to better handle radicals and shift levels toward a
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healthy balance. The naturally occurring antioxidant enzymes in skeletal muscle include
catalase, glutathione peroxidase (GPX), and superoxide dismutase (SOD). Under normal
conditions, ROS generation is significantly higher in type IIB muscle fibers than type I or
type IIA, whereas ROS clearance rates are highest in type I fiber due to higher levels of
antioxidant enzymes (Anderson & Neufer, 2006). During conditions of inflammation and
disease, ROS concentrations are elevated beyond the capacity of antioxidant handling.
ROS also affect the regulation of K+ channels, plasma membrane Ca2+ channels
and intracellular Ca2+ channels in muscle tissues (Hool, Di Maria, Viola, & Arthur, 2005;
Tang, Santarelli, Heinemann, & Hoshi, 2004). Maintenance of redox potential in
myocytes is important because hypoxic conditions will inactivate K+ channels,
decreasing carbon monoxide (CO) production and muscle metabolism while increasing
ROS generated. This condition fails to maintain redox homeostasis and results in cell
injury or dysfunction (Hoshi & Lahiri, 2004).
Uncontrolled oxidative stress acts as a feed-forward process, whereby the
increased concentration of ROS enhances intracellular and extracellular production of
ROS. Subsequent deleterious effects include lipid perodixation, damage to cell
membranes and organelles, disrupted signaling pathways, apoptosis, and muscle atrophy.
Lipid peroxidation (LPO) is a chain reaction initiated and furthered by oxygen free
radicals. ROS target double bonds of polyunsaturated fatty acids (PUFAs), and
compromise the integrity of mitochondrial membranes, which contain high levels of
PUFAs (Chance, Sies, & Boveris, 1979).
When these mitochondrial membranes become perforated due to the pro-oxidant
state, cytochrome c is released into the cytosol inducing caspase 9 signals for intrinsic
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cell apoptosis. Once inside the cytosol, cytochrome c binds to apoptotic protease
activating factor 1, allowing for the additional binding of a pro-caspase 9 zymogen in the
presence of adenosine triphosphate (ATP). This newly formed complex autoactivates
caspase 9, and signals caspase 3 downstream, inducing programmed cell death. Hydrogen
peroxide (H2O2) and superoxide (O2-) may activate the p53 gene inducing apoptotic
events as well. p53 directly activates the Bax gene (apoptotic factor), which binds to a
mitochondrial membrane-bound receptor and opens channels leading to a release of
cytochrome c and pro-caspase 9 (Chandra, Samali, & Orrenius, 2000; Feng Gao et al.,
2001). This mitochondrial (intrinsic) pathway differs from the death receptor pathway,
whereby signals, such as TNFα, bind to a plasma membrane-bound Fas ligand receptor,
and stimulate apoptosis via caspase 8 (Fulda & Debatin, 2006). Additionally, activated
p53 translocates to the nucleus where it induces gene expression (p21) preventing cell
division (Cui, Schroering, & Ding, 2002).
Deoxyribonucleic Acid Damage
Beyond membrane damage, uncontrolled oxidative stress may augment or
individually disrupt deoxyribonucleic acid (DNA) transcription and synthesis. Hydroxyl
radicals (OH) have been shown to cause DNA base modification or fragmentation (Van
Remmen, Hamilton, & Richardson, 2003). Disruption of the genome and replication
processes following radiation and chemotherapy is referred to as “genotoxic stress”
(Simonatto et al., 2011). The main forms of DNA damage likely to occur following DOX
administration are ROS-induced single-strand break (SSB), topoisomerase II-mediated
double-strand break (DSB), and apoptotic DNA fragmentation (Swift, Rephaeli,
Nudelman, Phillips, & Cutts, 2006). DOX treatment causes early event H2O2
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accumulation, which may be responsible for oxidative DNA lesions in cardiomyocytes
(L'Ecuyer et al., 2006). These oxidative lesions are readily repaired upon removal of
oxidants by free radical scavengers, such as N-acetyl cysteine (L'Ecuyer et al., 2006).
Non-oxidative, DOX-induced DNA damage, however, is less prone to rapid repair.
Specifically, anthracycline-induced DNA lesions include oxidized pyrimidines and 8hydroxyguanine (L'Ecuyer et al., 2006).
When DNA templates are damaged (i.e., lesions), cells stall at checkpoints before
replication and mitotic chromosome separation at the transition from G1 to S phase and
G2 to M phase (fork stalls). These delays facilitate the maintenance of proper DNA
sequences and prevention of accumulated DNA alterations (Nelson & Kastan, 1994). At
the G1 checkpoint, the tumor suppressor protein, p53, acts as a major regulator.
Following DNA damage, p53 levels rapidly increase and signal transduction pathways
lead to G1 cycle arrest or apoptosis (Kastan, Onyekwere, Sidransky, Vogelstein, & Craig,
1991). In myoblasts, p53 transactivates p21 to arrest the cell cycle following DOX
treatment. Terminally differentiated myotubes, however, do not exhibit p53 activation of
p21 or Bax genes, yet cell death occurs when exposed to DSB-inducing agents, like DOX
(Fortini et al., 2012).
Intercalative antibiotics, such as DOX, generate protein-linked DNA strand
breaks via topoisomerase II (TOP2) inhibition (Tewey, Rowe, Yang, Halligan, & Liu,
1984). Topoisomerases are enzymes that regulate the intertwining of DNA double-helical
structure. Mammalian TOP2 catalyzes topological isomerization reactions, via binding
DNA and passing the DNA strand to correct base pair structures and over-winding. The
TOP2-DNA union is referred to as a “cleavable complex.” DOX stabilizes these
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topoisomerase-DNA complexes, stalling replication forks. The stabilization of the
“cleavable” TOP2-DNA complex pauses strand passing activity, and prevents DNA
replication and RNA synthesis (Tewey et al., 1984). Beyond stabilizing the complex,
DOX intercalates elsewhere on DNA, binding tightly and further damaging strand
integrity. Furthermore, inability to cleave the stabilized complex leaves a lesion, which
results in a DNA DSB (Swift et al., 2006). In response to DNA damage, an apoptotic
reaction is signaled.
DNA damage response (DDR) is a complex network involving repair factors and
cell cycle regulators when genotoxic stress is induced (Ciccia & Elledge, 2010).
Checkpoints for DNA damage repair are at transitions from G1/S and G2/M phases
(Simonatto et al., 2011). If repair is not successfully completed, cells are destined to
apoptotic fates. Oxidative stress in terminally differentiated muscle cells may decrease
base excision repair (BER) capacity and lead to accumulation of SSBs, but cell death is
not inevitable in post-mitotic cells. DOX-induced muscle cell death is mainly attributed
to the activation of p53 by topoisomerase II DSB (Fortini et al., 2012). Similarly, Müller
and colleagues (1997) report apoptosis in skeletal muscle to be dependent on RNA
synthesis disruption rather than oxidative damage, which requires higher concentrations
to signal apoptosis. When DNA chromatin is damaged, histone H2AX is phosphorylated
and forms foci at the injured site (Kobayashi et al., 2002).
Doxorubucin and Skeletal Muscle
The toxic effects of DOX on cardiac muscle are well documented, but similar
parallels in characteristics of DOX-induced changes have been shown following single
i.p. DOX injections with losses in skeletal muscle mass and myofibrillar disorganization
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(Doroshow, Tallent, & Schechter, 1985). Both Type 1 and Type 2 muscle fibers decrease
in size following single limb DOX perfusion (Bonifati et al., 2000). Additionally, DOX
may upset excitation-contraction (EC) coupling mechanisms by altering SR Ca2+
transport, thereby reducing muscle force production (Hidalgo, Bull, Behrens, & Donoso,
2004; van Norren et al., 2009). Studies investigating cardiac muscle have shown no
changes in Ca2+ sensitivity, but found inhibition of SR uptake and release following DOX
treatments (Chugun et al., 2000).
Our lab demonstrated that skeletal muscle, similar to cardiac tissue, exhibited
severe functional declines in a time-dependent fashion following DOX injections
(Hayward et al., 2013). Additionally, proteolysis of skeletal muscle occurs following
DOX injections, resulting in degradation of myofibrillar actin (Smuder, Kavazis, Min, &
Powers, 2011b). Subsequently, this proteolysis may be linked to decreased muscle mass,
as muscle cross-sectional area is reduced following DOX administration (Mcloon,
Falkenberg, Dykstra, & Iaizzo, 1998). Functionally, patients who were treated with DOX
displayed reduced handgrip strength and quicker rates of fatigue (Stone et al., 1999).
Although i.p. DOX treatment does not affect limb muscles as severely as the heart or
diaphragm, cellular disruption, catabolism, and functional declines are evident
(Doroshow et al., 1985; Gilliam et al., 2009; Gilliam et al., 2012). Furthermore, DOX
treatment down-regulates contractile gene expression to include myosin-binding protein
H, myosin light chain 4, and troponin T type 1 (Simonatto et al., 2011). Clinical DOX
treatment clearly initiates skeletal myotoxic consequences.
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Skeletal Muscle Growth
Skeletal muscle is a dynamic, plastic tissue adept to hypertrophy in response to
growth factors, nutrition, and exercise (Evans, 2004). The growth and development of
skeletal muscle is mediated by a process whereby myoblasts produce myogenic
regulatory factors (MRFs), which allow further development and differentiation of a large
number of different cell types into muscle (Lowe & Alway, 1999; Megeney & Rudnicki,
1995). The MRFs are a family of basic helix-loop-helix (bHLH) muscle specific
regulatory proteins expressed exclusively by myonuclei and activated by satellite cells.
MRFs contain a basic region that facilitates DNA binding and HLH domain mediating
dimerization (Davis, Cheng, Lassar, & Weintraub, 1990). The HLH motif in MRFs
consists of α-helices, separated by a variable loop region. The consensus DNA sequence
5’-CANNTG-3’, referred to as an “E-box,” serves as the DNA target site for the basic
region (Murre et al., 1989). Activation of gene expression by MRFs requires
heterodimerization with another bHLH protein, which is typically from the E-protein
family. The bHLH E-proteins, E12 and E47, are 2 splice variants of the E2A gene that
are ubiquitously expressed and most frequently dimerize with MRFs (Lassar et al., 1991).
Once MRF-E protein heterodimers are formed, the DNA-binding domain binds to
a target E-box (CANNTG) site. The E-box sequence of DNA is found in the regulatory
region of many skeletal muscle-specific genes (Siu, Donley, Bryner, & Alway, 2004).
Downstream targets are then activated, leading to the expression of muscle structural
genes (contractile proteins) and generation of differentiated muscle phenotypes.
Additionally, the MRFs interact with MEF2 family of MADS-box transcription factors,
including MEF2A, -B, -C and –D. Not all skeletal muscle genes have E-boxes, and may
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require other factors to activate transcription (Hauschka, 1994). MEF2 factors bind to
MRF basic domains increasing conversion of non-muscle cells with MRFs (Molkentin,
Black, Martin, & Olson, 1995). MRFs autoregulate their own expression and induce
MEF2 expression. MEF2 factors bind to promoters of myogenic bHLH genes,
reinforcing their maintenance and transcription in a positive feedback fashion (Olson,
Perry, & Schulz, 1995).
MRFs include the transcription factors: MyoD, Myf5, myogenin and Mrf4. These
transcription factors act by increasing satellite cell proliferation and differentiation into
myoblasts. Functions of MRFs overlap, but are distinct in function with one rescuing
myoblast development in the absence of individual factors. MyoD and Myf5 are
expressed in proliferating myoblasts, and are referred to as primary MRFs. Myogenin and
Mrf4, or secondary MRFs, are present in myocytes in the process of terminal
differentiation. MyoD and Myf5 are expressed initially in proliferating myoblasts and
differentiating muscle, promoting entry into the cell cycle (Sabourin & Rudnicki, 2000).
Myogenin and Mrf4 are expressed later following myocyte fusion, promoting
differentiation and cell cycle exit (Hinterberger, Sassoon, Rhodes, & Konieczny, 1991).
Upstream of MRFs, the paired-box (Pax) family of transcription factors signal the
activation of satellite cells for growth and repair of skeletal muscles. Specifically, Pax3
and Pax7 are expressed uniquely in satellite cells. Upon injury, Pax7-expressing satellite
cells migrate to the damaged tissue. The Pax transcription factor levels are reduced with
concurrent increase of Myf5 and MyoD, leading to differentiation of myoblasts (Braun,
Rudnicki, Arnold, & Jaenisch, 1992; Rudnicki et al., 1993). Cells expressing Myf5 and
MyoD expand and proliferate myoblasts. After cue for differentiation, myoblasts exit the

18
cell cycle as myotubes and express myogenin and p21 (Halevy et al., 1995). The
terminally differentiated, multinucleated myotubes are distinguished by expression of
myosin heavy chain (MyHC) and troponin T.
In the event that p53 signals nuclear apoptosis in skeletal muscle cells, the whole
myofiber is not necessarily degraded. Due to the multinucleated nature of skeletal muscle
fibers, individual myonuclear apoptosis can occur without complete cell death (Primeau,
Adhihetty, & Hood, 2002). The nuclei selected for apoptosis are degraded without
affecting the survival of other nuclei in the shared cytoplasm or causing cell destruction
(Primeau et al., 2002).
Satellite Cells
The regenerative properties of skeletal muscle are due to progenitor cells known
as satellite cells (SCs). In adult muscle, SCs are small mononucleated skeletal muscle
precursor cells between the basal lamina of the muscle and sarcolemma of myofibers. In
adult tissue, approximately 5% of myonuclei in muscle fibers are within SCs (Bischoff,
1994; Zammit & Beauchamp, 2001). These unstressed cells are quiescent and arrested at
an early stage of the myogenic program. Following injury or in response to increased
functional demand, SCs become activated, rapidly divide, and exit the cell cycle. Next,
SCs migrate to the site of injury, proliferate, and differentiate into myoblasts.
Cytoplasmic volume increases and organelles develop, and the SC nuclei become
myonuclei. The myoblasts fuse to one another, forming multinucleated myotubes, or fuse
in place of damaged fibers, repairing damaged myofibers (Moss & Leblond, 1971). Some
of the proliferating SCs do not differentiate but rather remain quiescent in the G0/G1
phase of the cell cycle. Adult myonuclei are unable to divide, so repair and growth of
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muscle depends on the availability of SCs to provide new myonuclei in adult muscle
fiber. Due to the insulated position of SCs, they are shielded from environmental
exposure such as genotoxic stress experienced with DOX (Pallafacchina et al., 2010).
Frequency of SCs differs among muscle fiber types, where red, oxidative fibers
have more than white, glycolytic fibers. Additionally, myonuclear density is higher in the
red fibers, likely due to higher metabolic activity. Although MRFs can induce other cell
types (fibroblasts, etc.) to a myogenic fate, SCs provide the largest pool of new myogenic
precursors in hypertrophying muscle fibers (Moss & Leblond, 1971; Schiaffino,
Bormioli, & Aloisi, 1976).
Pax7 is a transcription protein expressed in cells that lie beneath the basal lamina,
and Pax7-null animals have no SCs (Seale et al., 2000). A number of SCs retain their
Pax7 expression while down-regulating MyoD, reversibly exit the cell cycle, and
reposition to the basal lamina until needed (Zammit et al., 2004). Continued Pax7
expression inhibits the pathway to myogenic fate (Wang & Conboy, 2010). After
activation and prior to differentiation, SCs express either Myf5 or MyoD (Cornelison &
Wold, 1997).
Somite Myogenesis
Vertebrate skeletal muscle is derived from somites formed during embryogenesis.
Somites are epithelial structures segmented from the paraxial mesoderm. The dorsal
portion of the somite is referred to as the dermomytome, which is comprised of dermal
and muscle progenitor cells (MPCs), whereas the ventral side will form the vertebral
column and ribs. The edges of the dermomyotome transitions from epithelial to
mesenchyme tissue, giving rise to the myotome, where the first differentiated myofibers
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exist. The dorsomedial (epaxial) region of the dermomyotome and myotome will become
the axial muscles of the back, while the ventrolateral (hypaxial) somite will generate
other trunk and limb muscles (Buckingham, 2001). At this stage, MPCs do not express
any MRFs or other skeletal muscle markers. Myogenesis in the myotome is induced by
both the notochord and neural plate cooperatively through members of the Wnt family of
growth factors to include Sonic hedgehog (Shh), Wnt-1, -3, and -4 proteins. Somatic cell
precursors, originating from the dermomyotome, migrate to limbs to commit to myogenic
fates (Brand-Saberi & Christ, 1999).
Gene ablation models have determined much of what is known about myogenesis,
whereby genes are deleted to determine the function served. MPCs are distinguished by
the presence of Pax3 and Pax7. When Pax3 fails to be expressed, muscle development is
impaired, with a complete loss of the hypaxial somite and loss of limb and some trunk
muscles (Dietrich, Schubert, Gruss, & Lumsden, 1999; Relaix, Rocancourt, Mansouri, &
Buckingham, 2004). In the absence of Pax3, epaxial muscles are less affected, but death
occurs mid-gestation (Chi & Epstein, 2002). Later in development, Pax7 becomes more
important, as MPCs cannot begin myogenic development without it. Lack of both Pax3
and Pax7 in MPCs will not allow entrance to myogenic lineage. The four bHLH
transcription factors, MyoD, Myf5, myogenin, and Mrf4, follow the Pax genes in the
myogenic development of the myotome.
Myogenic identity of cells is signaled by the determinant transcription factors,
Myf5 and MyoD. Individual disruption of Myf5 or MyoD in mice delays formation of
hypaxial and epaxial muscles, but no gross defects are evident in differentiation due to
functional redundancy of primary MRFs (Braun et al., 1992; Rudnicki, Braun, Hinuma,
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& Jaenisch, 1992). With losses in both Myf5 and MyoD, mice show reduced muscle
mass due to defective myoblast formation (Rudnicki et al., 1993). Additionally, severe
defects occur when differentiating secondary factors fail to be expressed. When
myogenin is absent in mice, myofiber formation is compromised causing animals to die
perinatally (Hasty et al., 1993; Nabeshima et al., 1993; Venuti, Morris, Vivian, Olson, &
Klein, 1995). Failure to express the Mrf4 gene leads to subtle deficiencies in myogenesis
such as reduced muscle specific genes, but no major defects in muscle development
occurs, likely due to overlapping functions of other factors (Olson, Arnold, Rigby, &
Wold, 1996).
Myogenic Regulatory Factors
Similar to the development of muscle during embryogenesis, muscle regeneration
in response to injury is highly dependent on the proliferative response of satellite cells
expressing myogenic regulatory factors (MRFs) to reconstruct functional myofibers. In
adult muscle, SCs follow similar genetic programming exhibited in embryonic
myogenesis, acting comparably to MPCs (Rudnicki, Le Grand, McKinnell, & Kuang,
2008). When satellite cells become committed to myogenic fate, they express both Myf5
and MyoD. In these active, proliferating myoblasts, early differentiation begins with the
expression of myogenin, followed by Mrf4. Cells are now referred to as myocytes, which
begin late differentiation, and form myotubes and ultimately fuse into myofibers (Figure
2.2) (Bentzinger, Wang, & Rudnicki, 2012). During late differentiation, myocytes also
express genes for muscle creatine kinase (MCK) and myosin heavy chain (MyHC),
responsible for contractile structure (Karalaki, Fili, Philippou, & Koutsilieris, 2009).
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Figure 2.2. Hierarchy of transcription factors regulating progression through the
myogenic lineage (Bentzinger et al., 2012)
Myogenic Factor 5
Myogenic factor 5 (Myf5) is the earliest expressed MRF in skeletal myogenesis
(Zweigerdt, Braun, & Arnold, 1997). Myf5, along with MyoD, is required for
determination to myogenic lineage. Myf5 interacts with Pax3 upstream of MyoD and
may be responsible for specifying muscle cell types (Tajbakhsh, Rocancourt, Cossu, &
Buckingham, 1997). Pax7 indirectly up-regulates Myf5 expression, inducing myoblast
proliferation (McKinnell et al., 2008). Decreased Myf5 expression early in myogenesis
inhibits differentiation. Defects in Myf5 expression have been shown to decrease
development of rib muscles and lead to perinatal or neonatal death, as evidenced by
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Myf5-/- knockout mice (Braun et al., 1992). Myf5-null myoblasts have been shown to
proliferate poorly and differentiate quickly (Montarras, Lindon, Pinset, & Domeyne,
2000). A predominant Myf5 expression versus MyoD in adult muscle has been shown to
direct greater myoblast proliferation and delayed differentiation, which may be
responsible for satellite cell self-renewal (Figure 2.3) (Rudnicki et al., 2008).

Figure 2.3. Satellite cell activation and differentiation in myogenesis and regeneration
(Karalaki et al., 2009)
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MyoD
MyoD is often considered to be the master regulatory gene in the myogenesis
process, due to its ability to modify numerous cell types (fibroblasts, chondrocytes,
neural cells) into myoblasts (Choi et al., 1990). It was the first discovered of the MRF
family. Failure to express MyoD early in development leads to reduced differentiation
and growth of muscles (Megeney, Kablar, Garrett, Anderson, & Rudnicki, 1996).
Cultured MyoD-null myoblasts grow quickly, but abnormally express target muscle
promoter genes (i.e., MCK, MyHC) and differentiate poorly (Sabourin, Girgis-Gabardo,
Seale, Asakura, & Rudnicki, 1999). When MyoD genes were deleted in mouse models,
Myf5 overexpressed and compensated for MyoD; despite vitality, muscle developed
abnormally and showed defects in regeneration (Martin, 2003). In spite of Myf5’s
compensatory capacity, MyoD more effectively targets a greater number of genes
inducing differentiation (Ishibashi, Perry, Asakura, & Rudnicki, 2005). Mice deficient in
both MyoD and Myf5 fail to form skeletal muscle, and die at birth (Martin, 2003). MyoD
mRNA has been shown to be more prevalent in fast glycolytic muscles and may play a
role in fiber-type determination. Mice lacking functional MyoD genes shifted fiber type
distribution and MyHC isoforms toward oxidative metabolism (Hughes, Koishi,
Rudnicki, & Maggs, 1997).
MyoD appears to be explicitly involved in DDR processes of skeletal muscle. In
response to DNA damage, an ABL (Abelson murine leukemia) tyrosine kinase
phosphorylates MyoD at tyrosine 30, arresting myoblasts at the G1/S checkpoint. MyoD
is prevented from activating muscle gene expression for synthesis (Simonatto et al.,
2011). Rather than performing transcriptional activation of muscle synthesis, MyoD
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recruits phosphorylated Nbs1 (Nijmegen breakage syndrome 1 gene) to target and repair
damaged chromatin. Nbs1 binds to phosphorylated H2AX foci of DSB and begins DNA
repair activities (Kobayashi et al., 2004). MyoD-null mice fail to repair DNA lesions,
allowing for proper synthesis activities to occur (Simonatto et al., 2013). When DNA
damage is detected at the G2/M phase checkpoint, MyoD cannot bind DNA sequences of
target genes, and cell arrest is induced before mitosis occurs.
Myogenin
Myogenin is expressed at the entry into the terminal differentiation program,
before fusion and differentiation of myoblasts to multinucleated myotubes (Smith,
Janney, & Allen, 1994; Yutzey, Rhodes, & Konieczny, 1990). Knockout mouse models
cause death at birth because myogenin-/- myoblasts are unable to fuse and form
differentiated myofibers (Hasty et al., 1993; Rawls et al., 1998; Vivian, Olson, & Klein,
2000). Muscle progenitors in these myogenin -/- mice still express MyoD and Myf5, but
muscle differentiation is defective (Martin, 2003). Unlike MyoD, myogenin transcript
mRNA has been found to be expressed greater in slow MyHC isoforms (Hughes et al.,
1993). Additionally, overexpression of myogenin results in greater oxidative metabolism,
with a decrease in glycolytic enzyme concentration (Hughes, Chi, Lowry, & Gundersen,
1999). Myogenin has been shown to increase following aerobic exercise in oxidative
muscle, such as the SOL (Siu et al., 2004).
Muscle Regulatory Factor 4
Muscle regulatory factor 4 (Mrf4) is expressed lastly during terminal
differentiation contributing to cell maturation, but also plays a role in the commitment of
cell to muscle lineage. Like Myf5, Mrf4 acts upstream of MyoD in determining skeletal
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muscle identity in the early somite (Kassar-Duchossoy et al., 2004). Inhibition of Mrf4
results in reduced cell fusion and differentiation. Mrf4-/- models demonstrate severe
muscle development deficiency. During early myogenesis, Mrf4 can act in place of
myogenin and increase expression of Mrf4 genes and partial development of ribcage, but
ultimately muscle development is defective and death occurs (Zhu & Miller, 1997). Mice
deficient in both Mrf4 and MyoD display form similar to myogenin-null mice, with
failure to differentiate myotubes (Rawls et al., 1998). Activities of Mrf4 are upregulated
by MEF2/myogenin interaction, as well. Mrf4 is involved in the maintenance of muscle
gene expression, and is present in mature myotubes. Expression of the other MRFs tend
to decrease postnatally, but Mrf4 remains constant throughout the lifespan, as seen in
mice (Bober et al., 1991; Hinterberger et al., 1991).
Myocyte Enhancer Factor 2
The myocyte enhancer factor 2 (MEF2) group of proteins are members of MADS
(MCM1, agamous, deficiens, serum response factor) box-containing family of
transcription factors. MEF2 was discovered as a protein from skeletal muscle nuclei,
which bound an A/T-rich sequence in muscle creatine kinase (MCK) gene promoters
(Gossett, Kelvin, Sternberg, & Olson, 1989). Structurally, MEF2 proteins have an amino
terminal composed of MEF and MADS boxes, which dimerize and bind DNA, and a
carboxyl terminal, involved in gene activation and kinase response (Black & Olson,
1998).
In vertebrates, MEF2 proteins act as co-factors for transcription during muscle
development. Evidence suggests MEF2 synergistically activates gene expression after the
onset of differentiation, implicating their role in later stages of terminal differentiation
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(Naya & Olson, 1999). In transgenic mice and cultured cells, MEF2 proteins bind to and
are necessary for the expression of myogenin and Mrf4 (Olson et al., 1995; Weintraub,
1993). Additionally, the myogenin and Mrf4 gene promoters do not have autoregulatory
binding sites, but, in fact, have a site for the MEF2 protein, which enhances promoter
activation (Edmondson, Cheng, Cserjesi, Chakraborty, & Olson, 1992; Naidu, Ludolph,
To, Hinterberger, & Konieczny, 1995).
MEF2C genes are expressed in several tissues, but first appear in the precardiac
mesoderm. Targeted inactivation of MEF2C in embryonic mice leads to lethal defects in
cardiac development (Lin, Schwarz, Bucana, & Olson, 1997). Throughout the mouse
embryo, MEF2C is also expressed in smooth muscles. MEF2A, -B, and -D are expressed
ubiquitously in various non-muscle cells (Lyons, Micales, Schwarz, Martin, & Olson,
1995). A few hours after myogenin is expressed in skeletal muscle-bound cells, MEF2C
becomes evident (Figure 2.4) (Edmondson et al., 1992). In adults, MEF2C expression is
limited to skeletal muscle, brain, and spleen, but its roles are essential in the origins of
cardiac and smooth muscle.
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Figure 2.4. Sites of MEF2 proteins influence in myogenesis (Olson et al., 1995)

Inhibitor of DNA Binding
The inhibitor of DNA binding (Id) protein is an HLH (helix-loop-helix) structure
that competitively binds to E-proteins. Id lacks the basic region for DNA binding seen in
the bHLH family of MRFs. The binding affinity of Id is substantially greater than MRFs
and acts as a negative regulator of the MRFs, sequestering potential of MRF dimer
partners (Benezra, Davis, Lockshon, Turner, & Weintraub, 1990). In normal
circumstances, Id is present and heterodimerizes with E-proteins, but the level expressed
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is not adequate to bind all dimer partners. Remaining E-proteins are able to
heterodimerize with MRFs and proceed in myoblast determination.
Id is expressed in a number of proliferating cells and typically decreases
expression upon induced differentiation (Biggs, Murphy, & Israel, 1992; Sun, Copeland,
Jenkins, & Baltimore, 1991). When levels increase substantially, the overexpression of Id
in myoblasts inhibit muscle differentiation (Üyashi et al., 1994). Additionally, Id proteins
are overexpressed in a nuÜber of human cancers and elevated expression is correlated
with higher histological grades (Ruzinova & Benezra, 2003). Other factors such as Twist,
Mist1, MyoR, and Sharp-1 also inhibit MRF transcriptional activities, DNA-binding, and
E-protein dimerization (Azmi, Ozog, & Taneja, 2004; Lemercier, To, Carrasco, &
Konieczny, 1998; Lu, Webb, Richardson, & Olson, 1999; Spicer, Rhee, Cheung, &
Lassar, 1996).
Doxorubicin and Myogenic Regulatory Factors
C2C12 myoblasts exposed to DOX in vitro down-regulate MyoD and myogenin
gene transcripts, while increasing levels of Id (Kurabayashi et al., 1993, 1994). As Id
competes for E-protein binding, elevated expression reduces availability for MRF
heterodimerization and transcript signaling for myoblast determination (Puri et al., 1997).
As previously mentioned, MyoD directly contributes to signaling of DNA repair
when myoblasts are exposed to DNA-damaging agents (i.e., DOX). C2C12 myoblasts
deficient in MyoD with inhibited ABL kinases exhibit impaired DNA repair activity
when exposed to DOX compared to wild type (WT) controls. Removing ABL kinase
inhibitors does not restore repair mechanisms, and requires functional MyoD to direct

30
phosphorylated Nbs1 to DNA-damaged foci on target genes, including myogenin
promoter and muscle creatine kinase (MCK) enhancer (Simonatto et al., 2013).
DOX arresting myoblasts at the G2/M phase does not allow MyoD to bind DNA
and activate differentiation (Kurabayashi et al., 1994; Puri et al., 1997). DOX-induced
arrest during the G2 phase reduces MyoD occupancy on myogenin and MCK target genes
(Simonatto et al., 2011). Puri and collegues (1997) exposed C2C12 mouse myoblasts to
DOX, ceasing the cell cycle at the same checkpoint, and demonstrated DNA synthesis
occurred without apoptosis following removal from DOX. These researchers found DOX
treatment led to an up-regulation in p21 proteins. p21 is a cyclin D kinase inhibitor,
which regulates passage through the cell cycle checkpoints. It responds to p53 by
mediating cell cycle arrest without inducing apoptosis. After exposure to DOX, p21
expression positioned myotubes in a reversible arrested state (Puri et al., 1997). p53
either directly signals apoptosis or p21 to arrest cells in a senescent state for DNA repair
before restarting the cell cycle.
Despite the shielded state of SCs to gentoxic stress while in a quiescent state,
once activated for muscle regeneration, SCs become susceptible to DNA damage. SCs
from MyoD-null mice exposed to DOX demonstrate DDR signaling; however, significant
delay in response and incomplete DNA repair persists up to 48 hours following damage.
Reintroduction of WT MyoD and ABL kinase restores repair ability and corrects DNA
lesions in treated SCs (Simonatto et al., 2013).
The reduced expression of myogenic markers, MyoD and Myf5, suggests a
decrease in the determination of satellite cells to become new muscle cells. An elevation
in Myf5 expression has been shown to proliferate myoblasts, with some reversing into a
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quiescent, satellite state for later differentiation. The increased SC number may assist
with muscle regeneration in the period following DOX treatment after its systemic
removal. The reduced expression of markers, Mrf4 and myogenin, will decrease the
ability of potential myocytes to differentiate into myotubes. The α-like RNA polymerase
core II subunit 3 (RPB3) specifically binds to myogenin, and not the other MRFs (Corbi
et al., 2002). DOX down-regulates RPB3 expression, which is correlated with inhibited
muscle differentiation. Activation of myogenin, and subsequent muscle differentiation,
may be blocked due to reduced RPB3 via DOX treatment (Martin, 2003). Exposure of
C2C12 myoblasts to genotoxic agents, such as DOX, reduced myotube formation by 6075% and inhibited expression of myogenin and MyHC seen late in the myogenic process
(Puri et al., 2002). Reduced levels of MyoD were not evident in this study, but E-box
DNA binding by MyoD is dramatically reduced following DOX treatment in myocytes
induced to differentiate (Puri et al., 1997).
As far as reductions in one MRF versus another, fluctuations can potentially
affect the muscle’s phenotype. In a normal, healthy state, oxidative (Type I) muscles
express higher levels of myogenin, while fast, glycolytic (Type II) muscles express
greater MyoD genes. Preserving myogenin in SOL and MyoD in EDL will presumably
maintain the normal muscle status. With endurance TM training adaptations acting more
upon oxidative muscles, increased/maintained muscle mass should be evident more so in
these tissues.
Exercise Preconditioning
Just as muscle can hypertrophy due to exercise and growth factors, significant
decreases in muscle size can occur as result of injury, disease, denervation, cachexia,
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prolonged disuse, sepsis, and oxidative stress (Tisdale, 2009). Aerobic exercise training
interventions are preventative measures used in mitigating the negative effects associated
with cancer treatments (Dimeo, Fetscher, Lange, Mertelsmann, & Keul, 1997; Dimeo,
Rumberger, & Keul, 1998; Chicco, Hydock, Schneider, & Hayward, 2006). Although
acute exercise increases free radical generation and tissue damage, repetitive training
appears to enhance antioxidant enzymes and oxidative repair systems (Gomez-Cabrera,
Domenech, Ji, & Viña, 2006; Radak, Chung, & Goto, 2008; Radak, Chung, Koltai,
Taylor, & Goto, 2008).
The effect of DOX generating uncontrollable ROS has been shown to decrease
skeletal muscle mass and fatigue resistance. Increases in ROS scavenging antioxidants
and attenuated functional deficits due to chronic aerobic exercise regimens prior to DOX
administration are widely reported (Ascensão et al., 2012; Chicco, Hydock, Schneider, &
Hayward, 2006; Chicco, Schneider, et al., 2006; Hydock et al., 2011b; Kanter, Hamlin,
Unverferth, Davis, & Merola, 1985; Wonders, Hydock, Schneider, & Hayward, 2008).
Short-term exercise protocols prior to DOX treatment have been shown to protect cardiac
and skeletal muscle function and elevate antioxidant enzymes, as well (Gomez-Cabrera,
Domenech, & Viña, 2008; Kavazis et al., 2014). Furthermore, acute aerobic exercise
attenuates myofibrillar degradation of actin in skeletal muscle and prevents increases in
apoptotic signaling following DOX i.p. injections (Smuder, Kavazis, Min, & Powers,
2011a; Smuder et al., 2011b). Even single bouts of endurance exercise have been shown
to reduce lipid peroxidation seen in myocardial tissues following DOX injections
(Wonders, Hydock, Schneider, & Hayward, 2008).
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As previously mentioned, Mrf4 is expressed at higher levels in adult muscles than
the other MRFs. Innervation is thought to alter the expression of these proteins, with
higher levels expressed following physical activity. Interestingly, with muscle
denervation, Myf5 and MyoD mRNA levels increase at least two-fold, whereas
myogenin transcript levels are elevated dramatically (Neville, Schmidt, & Schmidt, 1992;
Voytik, Przyborski, Badylak, & Konieczny, 1993). When re-innervated, however,
transcript levels rapidly return to basal conditions, without altering Mrf4 expression.
Mice subjected to immobilization (muscle disuse) had increased levels of myogenin
mRNA in the fast-twitch plantaris muscle while in lengthened positions. Shortened
positions decreased muscle mass and Mrf4 mRNA levels in the slow-twitch soleus (SOL)
muscle (Loughna & Brownson, 1996). Despite increases of mRNA following denervation
and immobilization, functional protein expression has not shown similar effects.
Effective protein expression appears to actually influence muscle mass versus mRNA,
with the exception of Mrf4 in the shortened position of the SOL muscle.
Neuromuscular activity, such as exercise, may influence functional MRF protein
expression in a more substantive manner. Siu and collegues (2004) found 24% greater
myogenin protein expression in rats following 8 weeks of treadmill (TM) training than
that of controls. Furthermore, oxidative metabolic enzyme levels and activity (i.e., citrate
synthase, cytochrome-c oxidases) exhibited linear increases, which may assist in handling
of ROS. As myogenin is a secondary MRF, its expression may be more readily examined
following acute exercise training. With single bouts of resistance exercise in humans,
MRF mRNA expression increases, but returns to basal levels within 24 hours (Psilander,
Damsgaard, & Pilegaard, 2003; Yang, Creer, Jemiolo, & Trappe, 2005). Haddad and
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Adams (2002) found greater myogenin transcript levels in rats with repeated bouts of
exercise. Repeated endurance exercise bouts may elicit similar elevations in functional
MRF protein levels. MRF transcript levels are found to decay 72 hours following
exercise bouts (Bickel et al., 2005). Kosek and colleagues (2006) investigated responses
to acute and chronic resistance training in humans. Following a single bout, no significant
changes occurred in protein expression, whereas mRNA increased in myogenin alone.
Following sixteen weeks of training, transcript levels of Myf5, MyoD, and myogenin
were increased from baseline. Protein levels Mrf4 and myogenin were significantly
higher after chronic resistance exercise (Kosek et al., 2006). No intermediate
measurements were recorded to distinguish transitions from MRF mRNA to protein
synthesis. Potential elevations of Myf5 and MyoD proteins may return to basal levels
after chronic training, which might be revealed following short-term exercise training.
MyoD has been implicated as a key regulator of myogenic transcription, due to its
association with ABL tyrosine kinase and ability to destabilize the non-functional DNATOP2 complex. If levels of MyoD are up-regulated/maintained with short-term exercise
training, muscle regeneration may be more viable following DOX treatment. Siu and
collegues (2004) did not observe significant MyoD increases in SOL muscles following a
TM protocol, but had the EDL been examined, levels may have been elevated due to
fiber type and MRF expression patterns (Hughes et al., 1997; Hughes et al., 1993; Siu et
al., 2004).
Conclusion
Skeletal muscle cells’ ability to regenerate is impaired following exposure to
DOX. p53-dependent apoptotic programs inhibit mitotic divisions and differentiation of
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new myocytes. Additionally, DOX produces DNA lesions and prevents repair due to its
inhibition of TOP2 function. Impaired ability to counter DNA damage in skeletal muscle
could lead to accumulated lesions and loss of muscle integrity over time. Chronically
elevated ROS production in skeletal muscle leads to proteolysis and cell death (Ji,
Gomez-Cabrera, & Vina, 2006).
Aerobic exercise enhances ROS handling in skeletal muscle and lessens cellular
damage attributed to oxidative stress. Additionally, aerobic training regimens will
theoretically maintain the expression of MyoD and other MRFs, increasing the ability to
maintain skeletal muscle DNA integrity following acute DOX treatment. DOX treatment
elevates Id protein expression and decreases muscle force production ex vivo.
Preconditioning, however, should potentially attenuate these DOX-induced dysfunctions
in skeletal muscle.
Much of the existing literature focuses on in vitro myoblast exposure to DOX. An
in vivo investigation may elucidate dynamic responses of muscle regeneration and
functional MRF expression with prior aerobic conditioning. This study potentially
demonstrated the therapeutic advantage of a short-term aerobic exercise intervention
before DOX treatment to preserve skeletal muscle and future developmental capacity.
Given the overlapping behaviors of MRFs, preservation of one or all should enhance
muscle regenerative capacity, or temper muscle loss, and attenuate functional reductions
following DOX treatment.
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CHAPTER III
METHODOLOGY
Experimental Design
Ten-week-old male Sprague Dawley rats (N=47) were randomly assigned to
either treadmill training (EXER, n=27) or sedentary (SED, n=20) groups. After 2 weeks
of endurance training, animals were randomly assigned to receive either a DOX or
placebo injection. Animals received either 15 mg/kg DOX or saline (SAL) injection
(Figure 3.1). Skeletal muscle function was measured ex vivo 24 hours post DOX/SAL
injections. A lipid peroxidation assay was used to determine levels of oxidative stress.
Western blot analysis was used to quantify the myogenic regulatory factor proteins,
Myf5, MyoD, myogenin and Mrf4, in SOL and EDL.
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Figure 3.1. Experimental Design for Treatments

Animals and Animal Care
All experimental procedures were approved by the University of Northern
Colorado Institutional Animal Care and Use Committee (Protocol #1407C-DH-R-17) and
were in compliance with the Animal Welfare Act guidelines (see Appendix A). Male
Sprague Dawley rats (10-week old) were purchased from Harlan (Indianapolis, IN). All
rats were housed in pairs under a 12:12 light-dark cycle at room temperature (20 ± 2°C),

38
and food (Harlan Teklad 2016 rodent chow) and water was provided ad libitum. Rats
were randomly assigned to one of four groups: (1) SED-SAL (Sedentary, Saline; n=10),
(2) SED-DOX (Sedentary, DOX; n=10) (3) EXER-SAL (Exercise, Saline; n=13) and (4)
EXER-DOX (Exercise, DOX; n=14). Body mass (g) for each animal was obtained at the
start and end of training and before sacrifice.
Exercise Training Protocol
Animals assigned to exercise preconditioning groups trained for 2 weeks on a
motorized treadmill during their dark cycle. In week 1, animals began running on a
treadmill for 10 minutes and duration was increased 10 minutes each day. During week 2,
animals trained for 60 minutes total per session (see Table 3.1). Speed remained constant
at 30 meters per minute. The treadmill work rate used represents an estimated 70% of
VO2max (Lawler, Powers, Hammeren, & Martin, 1993). When necessary, rats were
motivated by light electric shock at the rear of treadmill lanes. An exercise regimen of
similar conditions provoked significantly less ROS generation in rats that trained on
treadmills compared to sedentary animals (Smuder et al., 2011b). Furthermore, human
experiments demonstrated the need for more than one exercise bout to prompt myogeninpositive stained satellite cells, and thus, differentiating myoblasts (Raue, Slivka, Jemiolo,
Hollon, & Trappe, 2006). All animals assigned to EXER completed training protocols.
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Table 3.1
Treadmill exercise training protocol
Day
1
2

3

4

5

6–7

8 - 12

Speed (m/min)

30

30

30

30

30

(Rest)

30

Duration (min)

10

20

30

40

50

(Rest)

60

Incline (%)

0

0

0

0

0

(Rest)

0

Drug Treatment
To eliminate acute effects of exercise, animals received injections 24 hours after
the completion of the last treadmill training session. One half of both sedentary (10) and
exercise (14) trained groups were randomly assigned to receive DOX hydrochloride
(Bedford Labs: Bedford, OH) injections. The remaining animals (23) received 0.9%
saline placebo. A bolus injection of 15 mg/kg DOX was delivered intraperitonally (i.p)
on the right side of the abdominal cavity. Control animals received an equivalent volume
of saline. Twenty-four hours after injections, rats were sacrificed and tissues extracted.
The period between exercise and injection allowed sufficient time for MRF protein
synthesis. Additionally, the twenty-four hour time period minimized effects due to
anorexia-associated catabolism following treatment. Animals treated with DOX
significantly reduce food and water intake within 24 hours to several days (Gilliam et al.,
2009). Muscle masses should not be significantly affected in this 1-day period.
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Isolated Muscle Function
Tissue Preparation
Animals were acutely anesthetized with sodium pentobarbital (50 mg/kg). After
animals were completely anesthetized, indicated by failure to respond to a tail pinch, the
soleus (SOL) and extensor digitorum longus (EDL) were be quickly excised from the
right hindlimb and transferred to a tissue bath of Krebs Henseleit buffer (120 NaCl, 5.9
KCl, 2.5 CaCl2, 1.2 MgCl, 25 NaHCO3, 17 glucose; in mM) for muscle function data
collection. Animals were sacrificed prior to recovery from anesthesia by removal of the
heart. Contralateral muscles were also be removed, trimmed free of connective tissue and
fat, blotted dry, weighed, flash frozen in liquid nitrogen and stored at -80°C for later
biochemical analysis.
The SOL and EDL muscles were chosen for examination to give a representation
of two different muscle types (Type I: SOL; Type 2: EDL). Muscles were removed 1 day
following the end of training because oxidative enzymes are not affected more than 48
hours after acute endurance exercise training (Siu, Donley, Bryner, & Alway, 2003). In
young humans, MRF mRNA levels peak 12 hours after exercise (Williamson, Godard,
Porter, Costill, & Trappe, 2000). mRNA transcripts, however, are not functional proteins.
In fact, MRF mRNA can be upregulated without activation of SCs (Lowe & Alway,
1999). MyoD and myogenin have been shown in myonuclei as early as 1 day post
functional overload in rodent models (Ishido, Kami, & Masuhara, 2004).
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Ex Vivo Muscle Function
Functional muscle data were obtained via electrostimulation of tissues in organ
baths (Radnoti: Monrovia, CA). Two electrodes surrounding the muscle in organ baths
provided stimulation. Muscle contraction forces were recorded using PowerLab data
acquisition hardware (ADInstruments: Colorado Springs, CO). Maximal twitch force was
achieved by adjusting muscle for optimal length, and subsequent change in voltage
applied (Grass Technologies: Warwick, RI).
The muscle stimulation methods follows the protocol reported by Hydock et al.
(2011). Muscles were allowed to stabilize in the warmed (37°C) and oxygenated (95%
O2/5% CO2) organ bath prior to functional data collection. Initial muscle tension was
adjusted to 0.5 g, and stimulated with a square-wave pulse duration of 0.5 ms at 40 V.
Muscle tension was increased by 0.2 g per stimulation (2-minute rest) until twitch force
reaches a maximum. Next optimal voltage was verified by increasing applied voltage by
increments of 5 V, allowing the same 2-minute rest period. Once maximal twitch force
was determined, the bath of Krebs-Henseleit buffer was be cycled for a new volume to
ensure proper electrolyte balance for ensuing fatigue resistance recording. The muscle
was allowed a recovery time of 30 minutes in fresh buffer before continuous stimulation
cycling. Pulse duration was increased to 500 ms while maintaining the determined
optimal length and voltage. The muscle was stimulated continuously every 1 second for 2
minutes to simulate fatiguing conditions (Hydock, Lien, Jensen, Schneider, & Hayward,
2011a). LabChart software (ADInstruments) was used to analyze force data acquired.
Measures of maximal force, maximal rate of force development, and maximal rate
of force decline were recorded during the single twitch force stimulation recordings.
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During the continuous, fatiguing protocol, force production were recorded in reference to
baseline levels every 10 seconds, for a total of 100 seconds.
Biochemical Analyses
Homogenate Preparation
The flash frozen left hindlimb muscles were homogenized in
radioimmunoprecipitation assay (RIPA) buffer (10:1) and protease enzyme inhibitors
(SigmaAldrich: St. Louis, MO). After manual homogenization, samples were sonicated to
increase nuclear protein recovery. Homogenates were then be spun in a microcentrifuge
for 10 minutes at 3000 g at 4°C. Total protein was quantified in samples using a Genesys
20 photospectrometer (ThermoSpectronic: Rochester, NY) at 562 nm according to the
bicinchronic acid (BCA) assay (Smith et al., 1985). A determined amount of RIPA buffer
was added to standardize protein concentration.
Lipid Peroxidation
The most abundant product of LPO is malondialdehyde (MDA), and it is
commonly assayed as an index of oxidative stress. LPO was determined using a
commercially available assay kit (BioxyTech MDA-586, Oxis Research: Foster City,
CA). Malondialdehyde and 4-hydroxyalkenals (MDA+4-HAE) were measured to
indicate cellular lipid peroxidation. 200 µL of sample homogenates were added to a
microcentrifuge tube. 650 µL of N-methyl-2-phenylindole in acetonitrile was added to
the sample and briefly vortexed. 150 µL of methanesulfonic acid was then be added and
vortexed, followed by a 60 minute incubation period at 45°C. Following the incubation
period, samples were centrifuged at 10,000 g for 10 minutes to remove turbidity.
Supernatants were then transferred to cuvettes for absorbency measurement using a
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spectrophotometer at 586 nm. Concentration of MDA+4-HAE was estimated from a
standard curve. Samples were run in duplicate, with reassay if samples vary by more than
5%.
Western Blotting
Western blot analysis was conducted on muscle samples for the presence of
MRFs in the SOL and EDL via SDS-PAGE. An equal volume of Lammeli buffer was
added to samples in a microcentrifuge polypropylene vial, reducing protein concentration
in half. Samples were heated in boiling water for 2 minutes, then chilled on ice for 5
minutes before 46 µg was loaded onto 4-20% gradient Tris-Glycine NuPage precast gels
(LifeTechnologies: Carlsbad, CA). Gels were run at 125 V (constant voltage) and 4 mA
current for 2 hours in a Xcell II blot module (Invitrogen, LifeTechnologies), until
proteins had migrated the whole gel. Proteins were transferred to 0.45 micron
polyvinylidene fluoride (PVDF) membranes over 90 minutes at 25 V and 100 mA.
Protein transfers to PVDF membranes were ensured by the presence of a SeeBlue® Plus2
protein ladder (Novex, LifeTechnologies). Membranes were blocked for 1 hour in 15 mL
of TBST + 5% milk, and then incubated with gentle agitation overnight in 10 mL of
primary antibodies. Membranes were then be washed in TBST three times for 5 minutes,
followed by incubation in appropriate species-specific secondary antibodies for 1 hour.
After three more 5-minute washes in TBST, membranes were prepared for protein band
detection.
Detection was executed by enhanced chemiluminescence (ECL) (C-Digit, Li-Cor:
Lincoln, NE), and ImagJ software (NIH: Bethesda, MD) was used to quantify protein
expression. Immediately before chemiluminescent imaging, 1.5 mL of luminol and

44
enhancer (SuperSignal West Femto Maximum Sensitivity Chemiluminescent Substrate,
ThermoScientific: Waltham, MA) was added to the membrane. The primary antibodies of
interest included rabbit monoclonal MyoD and myogenin (Santa Cruz Biotechnology:
Dallas, TX) and Myf5 and Mrf4 (Abcam: Cambridge, MA). The rabbit monoclonal antiGAPDH (Abcam) was used as a loading control. Molecular weights of protein bands
were ensured in reference to a MagicMark™ XP standard ladder (Novex,
LifeTechnologies). Secondary antibodies (Santa Cruz Biotechnology) corresponded to
associated species (rabbit) and include horseradish peroxidase (HRP) for adequate
reactivity.
Statistical Analysis
Data were analyzed using GraphPad Prism statistical software (GraphPad:
LaJolla, CA) and presented as means ± standard error (mean±SEM). A two-factor
(Exercise X Drug) analysis of variance (ANOVA) was used to determine main effects
and interactions of treatments in muscle mass, muscle force production, lipid
peroxidation, and MRF concentration. If a significant F-value was observed, a Tukey
post-hoc pair-wise comparison identified significant differences between groups.
Variables included the four MRF proteins concentrations, muscle masses, and force
parameters from ex vivo analysis in each of the groups (maximal twitch, maximal rate of
force production, and maximal rate of force decline). Muscle fatigue responses were
analyzed with maximal twitch force obtained every 10 seconds and compared to baseline
measures. For this study, muscle fatigue was defined at the point at which force
production was below 75% of baseline skeletal muscle twitch force. For statistical
procedures, significance was set at the α=0.05 level.
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CHAPTER IV
RESULTS
The purpose of this study was to determine the effects of acute DOX
administration on skeletal muscle force production and fatigue resistance, lipid
peroxidation (LPO), and MRF expression in skeletal muscles. Additionally, this study
investigated the effects of short-term endurance exercise training on muscle force
production and fatigue resistance, LPO, and MRF expression. This chapter presents
findings of the study.
General Observations
Table 4.1 presents animal characteristics at the time of injection after training and
at the time of sacrifice. At the time of injection, animal body mass was significantly
different between groups. An activity effect was observed with SED animals exhibiting
significantly greater body mass, F (1, 43) = 16.72, p<0.05. Post hoc testing revealed body
mass to be higher in SED-SAL and SED-DOX than EXER-SAL, p<0.05.
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Table 4.1
Animal Characteristics.
SED-SAL SED-DOX EXER-SAL EXER-DOX
Injection Body Mass (g) 360 ± 11 a 364 ± 10 a

322 ± 5

335 ± 7

Sacrifice Body Mass (g) 360 ± 12 b 354 ± 9 b

326 ± 6

329 ± 6

SOL Mass (mg)

135 ± 7

140 ± 4

132 ± 5

133 ± 5

EDL Mass (mg)

142 ± 5

138 ± 8

135 ± 4

141 ± 4

SED-SAL = sedentary saline, n=10; SED-DOX = sedentary doxorubicin, n=10; EXERSAL = exercise saline, n=13; EXER-DOX = exercise doxorubicin, n=14. Values are
means ± SEM.
a
= Significantly greater than EXER-SAL (p<0.05).
b
= Significantly greater than EXER-DOX (p<0.05).
Significant activity effect in injection and sacrifice body mass (p<0.05).
At the time of sacrifice, a similar activity effect existed with greater mass in SED
animals, F (1, 43) = 13.42, p<0.05. Post hoc testing revealed that EXER-DOX body mass
was significantly less than SED-SAL and SED-DOX, p<0.05. A significant drug effect
was observed in body mass change, as well, F (1.43) = 34.65, p<0.05 (Figure 4.1). Rats
receiving SAL slightly gained body mass after injections (1%) while those receiving
DOX decreased body mass (2.5%). Within groups, body mass changes were not
significantly different (p>0.05).
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Figure 4.1. Change in body mass following injections.
SED-SAL = sedentary saline, n=10; SED-DOX = sedentary doxorubicin, n=10; EXERSAL = exercise saline, n=13; EXER-DOX = exercise doxorubicin, n=14. Values are
mean ± SEM.
a
= Significantly different from EXER-SAL (p<0.05).
b
= Significantly different from SED-SAL (p<0.05).
Significant drug effect (p<0.05).
There was no significant difference in absolute SOL mass observed between
groups, p>0.05 (Figure 4.2A). Similarly, when SOL mass was corrected for body mass,
no significant difference was detected, p>0.05 (Table 4.2, Figure 4.3A). Absolute EDL
masses displayed no significant differences for main effects or exercise by drug
interaction, p>0.05 (Figure 4.2B). When corrected for body mass, an activity effect was
detected with endurance-trained animals demonstrating higher relative EDL mass, F = (1,
43) = 4.871, p<0.05 (Figure 4.3B).
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Figure 4.2. Tissue mass at time of sacrifice, SOL (A) and EDL (B).
SOL = soleus, EDL = extensor digitorum longus, SED-SAL = sedentary saline, n=10;
SED-DOX = sedentary doxorubicin, n=10; EXER-SAL = exercise saline, n=13; EXERDOX = exercise doxorubicin, n=14. Values are mean ± SEM.
Table 4.2
Tissue mass relative to body mass.
SED-SAL

SED-DOX

EXER-SAL

EXER-DOX

SOL (mg/g BM)

0.37 ± 0.01

0.39 ± 0.01

0.40 ± 0.01

0.41 ± 0.01

EDL (mg/g BM)

0.39 ± 0.01

0.39 ± 0.02

0.42 ± 0.01

0.43 ± 0.01

SOL = soleus, EDL = extensor digitorum longus, SED-SAL = sedentary saline, n=10;
SED-DOX = sedentary doxorubicin, n=10; EXER-SAL = exercise saline, n=13; EXERDOX = exercise doxorubicin, n=14. Values are mean ± SEM.
Significant activity effect in EDL (p<0.05).
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Figure 4.3. Tissue mass relative to body mass, SOL (A) and EDL (B).
SOL = soleus, EDL = extensor digitorum longus, BM = body mass, SED-SAL =
sedentary saline, n=10; SED-DOX = sedentary doxorubicin, n=10; EXER-SAL =
exercise saline, n=13; EXER-DOX = exercise doxorubicin, n=14. Values are mean ±
SEM.
Significant activity effect in EDL (p<0.05).
Isolated Muscle Function
Maximal Twitch Force
Once right SOL and EDL were excised, muscles were placed in organ baths filled
with Krebs-Henseleit buffer. Tension and voltage were gradually increased to determine
optimum conditions as detected by maximal twitch force elicited. Additionally, rate of
force production and rate of force decline were measured from maximal twitch force
tracings.
No significant differences were observed in SOL maximal twitch forces between
groups, p>0.05 (Table 4.3). After adjusting force relative to tissue mass, significance
remained undetected (Figure 4.4). Rates of force production and decline were also not
significantly different between groups, p>0.05.
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Table 4.3
SOL muscle twitch forces
SED-SAL

SED-DOX

EXER-SAL

EXER-DOX

Maximal Twitch
Force (mN)

37 ± 3

50 ± 5

44 ± 4

46 ± 4

Relative Maximal
Twitch Force
(mN/g)
Maximal Rate of
Force Production
(mN/s)
Maximal Rate of
Force Decline
(mN/s)

249 ± 36

287 ± 29

258 ± 28

296 ± 41

4916 ± 463

6376 ± 699

5478 ± 670

5536 ± 589

- 1715 ± 193

- 1935 ± 160

- 2027 ± 117

- 2255 ± 154

SOL = soleus, SED-SAL = sedentary saline, n=10; SED-DOX = sedentary doxorubicin,
n=10; EXER-SAL = exercise saline, n=13; EXER-DOX = exercise doxorubicin, n=14.
Values are mean ± SEM.
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Figure 4.4. SOL Maximal twitch force values. Maximal twitch (A), maximal twitch
relative to tissue mass (B), rate of force production (C), rate of force production (D), SOL
rate of force decline.
SOL = soleus, SED-SAL = sedentary saline, n=10; SED-DOX = sedentary doxorubicin,
n=10; EXER-SAL = exercise saline, n=13; EXER-DOX = exercise doxorubicin, n=14.
Values are mean ± SEM.
No significant differences were seen between groups in EDL maximal twitch
forces, p>0.05 (Table 4.4). Similarly, no significance was observed after correcting for
tissue mass. Rates of force production and decline were not significantly different
between groups, as well (Figure 4.5).
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Table 4.4
EDL muscle twitch forces
SED-SAL
Maximal Twitch
Force (mN)

79 ± 7

SED-DOX
90 ± 9

EXER-SAL

EXER-DOX

92 ± 8

77 ± 12

Relative Maximal
511 ± 26
603 ± 69
632 ± 51
545 ± 80
Twitch Force
(mN/g)
Maximal Rate of
14407 ± 1199 17851 ± 2060
18242 ± 1772 14966 ± 2603
Force Production
(mN/s)
Maximal Rate of
- 8489 ± 690
- 10410 ± 1155 - 11583 ± 1272 - 9308 ± 1380
Force Decline
(mN/s)
EDL = extensor digitorum longus, SED-SAL = sedentary saline, n=10; SED-DOX =
sedentary doxorubicin, n=10; EXER-SAL = exercise saline, n=13; EXER-DOX =
exercise doxorubicin, n=14. Values are mean ± SEM.
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Figure 4.5. EDL Maximal twitch force values. Maximal twitch (A), maximal twitch
relative to tissue mass (B), rate of force production (C), rate of force production (D), SOL
rate of force decline.
EDL = extensor digitorum longus, SED-SAL = sedentary saline, n=10; SED-DOX =
sedentary doxorubicin, n=10; EXER-SAL = exercise saline, n=13; EXER-DOX =
exercise doxorubicin, n=14. Values are mean ± SEM.
Fatigue
After cycling Krebs-Henseleit buffer and allowing muscles to rest for 30 minutes,
a 2-minute continuous stimulation at determined optimal length and voltage was
performed. Time-to-fatigue was determined when muscles produced 75% of baseline
force production.
In the SOL, SED-DOX and EXER-SAL generated less than 75% baseline force
40 seconds into fatiguing protocol. At the 50-second time point, EXER-DOX force
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production was below 75%. SED-SAL recorded the greatest fatigue resistance with
twitch forces lower than 75% of baseline by 70 seconds (Figure 4.6).
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Figure 4.6. SOL fatigue resistance.
SOL = soleus, SED-SAL = sedentary saline, n=10; SED-DOX = sedentary doxorubicin,
n=10; EXER-SAL = exercise saline, n=13; EXER-DOX = exercise doxorubicin, n=14.
Values are means ± SEM.
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In the EDL, SED-SAL fatigued quickest with twitch forces less than 75% at the
40-second time point. SED-DOX, EXER-SAL, and EXER-DOX groups’ forces fell
below fatigue threshold at 50 seconds (Figure 4.7). The fast-twitch muscle typically
fatigues a greater rate than slow, oxidative muscles. Ex vivo force production of the EDL
did not fatigue faster to levels below 75% of initial force values but, at the end 100
seconds, all forces were below those of SOL.
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Figure 4.7. EDL fatigue resistance.
EDL = extensor digitorum longus, SED-SAL = sedentary saline, n=10; SED-DOX =
sedentary doxorubicin, n=10; EXER-SAL = exercise saline, n=13; EXER-DOX =
exercise doxorubicin, n=14. Values are means ± SEM
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Biochemical Analyses
Lipid Peroxidation
SOL and EDL homogenates obtained from rats 1 day after saline or DOX
injection were analyzed for markers of lipid peroxidation (MDA+4-HAE). All data from
LPO analysis are presented in Table 4.5. In SOL, a significant drug effect was observed
in rats receiving SAL exhibited higher levels of MDA+4-HAE, F = (1, 43), p<0.05
(Figure 4.8A). EXER-SAL animals presented significantly greater indices of lipid
peroxidation than SED-DOX and EXER-DOX. No activity effect or interaction was
detected in the SOL. In the EDL, a significant activity effect was observed with TM
animals presenting higher MDA+4-HAE, F = (1, 43) = 4.08, p<0.05 (Figure 4.8B). No
drug effect or interaction was detected.

Table 4.5
Lipid peroxidation levels
SED-SAL

SED-DOX

EXER-SAL

EXER-DOX

SOL (pmol/mg)

329 ± 24

275 ± 17 a

398 ± 36

292 ± 17 a

EDL (pmol/mg)

214 ± 14

225 ± 17

283 ± 28

288 ± 44

SOL = soleus, EDL = extensor digitorum longus, SED-SAL = sedentary saline, n=10;
SED-DOX = sedentary doxorubicin, n=10; EXER-SAL = exercise saline, n=13; EXERDOX = exercise doxorubicin, n=14. Values are mean ± SEM.
a
= Significantly different from EXER-SAL (p<0.05).
Significant drug effect in SOL.
Significant activity effect in EDL.
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Figure 4.8. Lipid peroxidation levels in hindlimb muscles, SOL (A) and EDL (B).
SOL = soleus, EDL = extensor digitorum longus, SED-SAL = sedentary saline, n=10;
SED-DOX = sedentary doxorubicin, n=10; EXER-SAL = exercise saline, n=13; EXERDOX = exercise doxorubicin, n=14. Values are mean ± SEM.
a
= Significantly different from EXER-SAL.
Significant drug effect in SOL (p=0.0033).
Significant activity effect in EDL (p<0.05).
Western Blotting
Expression of myogenic regulatory factor proteins, Myf5, MyoD, Mrf4, and
myogenin, were measured in SOL and EDL homogenates to evaluate the influence of
endurance exercise and DOX on these transcription factors. Forty-six µg of protein from
SOL and EDL homogenates were added to 4-20% Tris-glycine precast gels and run
through SDS-PAGE. MRF levels were assessed by chemiluminescence and expressed
relative to GAPDH as a loading control. It should be noted that no significant GAPDH
activity of drug main effects or interactions (p>0.05) were observed suggesting that the
exercise or drug treatments did not affect the loading control. All Western blot data are
presented in Tables 4.6 (SOL) and 4.7 (EDL).
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Table 4.6
SOL Myogenic Regulatory Factor (MRF) levels
SED-SAL
SED-DOX

EXER-SAL

EXER-DOX

0.44 ± 0.10 a 0.73 ± 0.14

0.92 ± 0.08

1.28 ± 0.22

1.29 ± 0.13

1.67 ± 0.13

1.46 ± 0.16

2.11 ± 0.31

0.50 ± 0.12

0.67 ± 0.14

0.81 ± 0.17

0.80 ± 0.16

Myogenic Factor 5
(Myf5)
MyoD
Myogenin

Muscle Regulatory
0.62 ± 0.18 0.80 ± 0.20
1.23 ± 0.18
1.22 ± 0.24
Factor 4 (Mrf4)
SOL = soleus, SED-SAL = sedentary saline, n=10; SED-DOX = sedentary doxorubicin,
n=10; EXER-SAL = exercise saline, n=13; EXER-DOX = exercise doxorubicin, n=14.
Values are mean ± SEM.
a
= Significantly different from EXER-DOX (p<0.05).
Significant activity and drug effect in Myf5 (p<0.05).
Significant drug effect in MyoD (p<0.05).
Significant activity effect in Mrf4 (p<0.05).

Table 4.7
EDL Myogenic Regulatory Factor (MRF) levels
SED-SAL
SED-DOX
Myogenic Factor 5
(Myf5)
MyoD
Myogenin

EXER-SAL

EXER-DOX

1.25 ± 0.23

1.25 ± 0.19

1.57 ± 0.19

1.49 ± 0.14

1.28 ± 0.20

1.55 ± 0.17

1.30 ± 0.07

1.13 ± 0.09

0.48 ± 0.15

0.64 ± 0.15

0.62 ± 0.11

0.67 ± 0.14

Muscle Regulatory
0.47 ± 0.12
0.52 ± 0.13
0.64 ± 0.09
0.46 ± 0.08
Factor 4 (Mrf4)
EDL = extensor digitorum longus, SED-SAL = sedentary saline, n=10; SED-DOX =
sedentary doxorubicin, n=10; EXER-SAL = exercise saline, n=13; EXER-DOX =
exercise doxorubicin, n=14. Values are mean ± SEM.
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Myogenic Factor 5
In the SOL, a 2-way ANOVA revealed a significant activity effect, with EXER
groups exhibiting higher levels of myogenic factor 5 (Myf5), F (1, 43) = 10.42, p<0.05
(Figure 4.9A). Additionally, a drug effect was observed, with DOX-treated groups
expressing higher Myf5, F (1, 43) = 4.267, p<0.05. No significant interaction was
observed. Post hoc tests revealed that SED-SAL expressed significantly less Myf5 than
EXER-DOX. In the EDL, no significant main effects were observed, and no interaction
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was detected (Figure 4.9B).

Figure 4.9. Myf5 expression levels, SOL (A) and EDL (B).
SOL = soleus, EDL = extensor digitorum longus, OD = optical density, SED-SAL =
sedentary saline, n=10; SED-DOX = sedentary doxorubicin, n=10; EXER-SAL =
exercise saline, n=13; EXER-DOX = exercise doxorubicin, n=14. Values are mean ±
SEM.
a
= Significantly different from EXER-DOX.
Significant activity and drug effect in SOL Myf5 (p<0.05).
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MyoD
In the SOL, a significant drug effect was observed, with DOX groups exhibiting
higher levels of MyoD, F (1, 43) = 5.382, p<0.05 (Figure 4.10A). No activity effect and
no interaction in SOL MyoD were detected. In the EDL, no significant main effects were
identified, and no interaction was observed (Figure 4.10B).
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Figure 4.10. MyoD expression levels, SOL (A) and EDL (B).
SOL = soleus, EDL = extensor digitorum longus, OD = optical density, SED-SAL =
sedentary saline, n=10; SED-DOX = sedentary doxorubicin, n=10; EXER-SAL =
exercise saline, n=13; EXER-DOX = exercise doxorubicin, n=14. Values are mean ±
SEM.
Significant drug effect in SOL MyoD (p<0.05).
Myogenin
In the SOL, no significant drug or activity effects or interaction were observed
(Figure 4.11A). In the EDL, no significant main effects or interaction were identified
(Figure 4.11B).
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Figure 4.11. Myogenin expression levels, SOL (A) and EDL (B).
SOL = soleus, EDL = extensor digitorum longus, OD = optical density, SED-SAL =
sedentary saline, n=10; SED-DOX = sedentary doxorubicin, n=10; EXER-SAL =
exercise saline, n=13; EXER-DOX = exercise doxorubicin, n=14. Values are mean ±
SEM.
Muscle Regulatory Factor 4
In the SOL, a significant activity effect was observed, with EXER groups
exhibiting higher levels of muscle regulatory factor 4 (Mrf4), F (1, 43) = 5.672, p<0.05
(Figure 4.12A). No drug effect or interaction in the SOL was detected. In the EDL, no
significant main effects were identified, and no interaction was observed either (Figure
4.12B).
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Figure 4.12. Mrf4 expression levels, SOL (A) and EDL (B).
SOL = soleus, EDL = extensor digitorum longus, OD = optical density, SED-SAL =
sedentary saline, n=10; SED-DOX = sedentary doxorubicin, n=10; EXER-SAL =
exercise saline, n=13; EXER-DOX = exercise doxorubicin, n=14. Values are mean ±
SEM.
Significant activity effect in SOL Mrf4 (p<0.05)
Summary
Acute DOX treatment and short-term endurance exercise did not significantly
affect skeletal muscle maximal twitch force production in the SOL or EDL. The time
taken to fatigue in both SOL and EDL was longest in sedentary animals receiving saline
injections. No absolute measures of tissue mass were significantly different but, after
correcting for relative mass, an activity main effect was observed with higher EDL
masses. No mass differences were seen in SOL.
An activity main effect in the EDL of EXER animals suggests elevated oxidative
stress as indicated by higher levels of lipid peroxidation. Surprisingly, lipid peroxidation
levels were higher in the SOL of SAL animals than SOL of DOX animals. Myf5
expression in the SOL was increased with both drug and exercise treatments. MyoD
expression in the SOL was increased with DOX treatment. Levels of Mrf4 in the SOL

65
were elevated with endurance training. No change was seen in SOL myogenin levels, and
no changes in Myf5, MyoD, Mrf4, or myogenin were observed in the EDL due to
exercise or DOX treatments.

66

CHAPTER V
MANUSCRIPT FOR PUBLICATION
Abstract
Doxorubicin (DOX) is a widely used anthracycline antibiotic used to treat a number of
hematological and solid tumor cancers. Dosage, however, is limited due to its toxic
effects in healthy tissues. Negative consequences include myotoxicity in skeletal muscle,
which may limit mobility and activities of daily living. The capacity for skeletal muscular
regeneration relies heavily of the activity of myogenic regulatory factor (MRF) proteins.
In vitro experiments with DOX depress the expression of MRFs but in vivo treatment
may elicit different responses. Endurance exercise has been shown to elevate MRF
expression, and may preserve MRFs following in vivo DOX-treatment.
Purpose: To determine the effect of short-term endurance training and acute DOX
administration of skeletal muscle force production and fatigue resistance, levels of lipid
peroxidation, and expression of MRFs. Methods: Ten week old male Sprague-Dawley
rats were randomly assigned to one of four groups: sedentary + saline (SED-SAL), SEDDOX, endurance exercise training + saline (EXER-SAL), or EXER-DOX. Animals
remained sedentary or performed treadmill training for two weeks. Twenty four hours
after the activity period, animals were injected with a bolus i.p. injection of DOX (15
mg/kg) or SAL. Twenty four hours after injection, soleus (SOL) and extensor digitorum
longus (EDL) skeletal muscles were removed for ex vivo function measures. Analyses of
lipid peroxidation (malondialdehyde and 4-hydroxyalkenals [MDA + 4-HAE]) and
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Western blotting for MRF expression (Myf5, MyoD, myogenin, Mrf4) were performed
on contralateral muscles. Endurance exercise significantly elevated Myf5 and Mrf4 in
the SOL (p<0.05). No significant differences existed in MRF expression levels in the
EDL. No significant muscle force production or fatigue resistance differences were
identified due to drug or activity treatment. MDA + 4-HAE was higher in the SOL of
SAL animals (p<0.05) and EDL of EXER animals (p<0.05). Conclusion: Short-term
endurance exercise elevated Myf5 and Mrf4 in slow, oxidative muscle after acute DOX
treatment. Endurance exercise prior to chemotherapy may augment skeletal muscles’
regenerative capacity following treatment, when loss of muscle mass is common.
Introduction
Muscle weakness and subsequent deterioration in activities of daily living are
common side effects of chemotherapy treatments prescribed to cancer patients (Bonifati
et al., 2000; Burckart, Beca, Urban, & Sheffield-Moore, 2010; Knobel et al., 2001). The
commonly used anthracycline antibiotic, doxorubicin (DOX; trade name: Adriamycin®)
has been shown to elicit consequences, which precede severe to fatal associations with its
cardiotoxic nature. Free radicals formed by iron-catalyzed reactions are implicated in
nuclear and mitochondrial damage inducing cell death (Bagchi, Bagchi, Hassoun, Kelly,
& Stohs, 1995; DeAtley et al., 1999; Rapozzi et al., 1998; Stathopoulos et al., 1997).
Much of the existing literature surrounding DOX-induced injury focuses on the effects
seen in the heart. More recently, research has elucidated serious skeletal muscle harm,
decreasing muscle size and function in response to DOX exposure (Doroshow, Tallent, &
Schechter, 1985; Gilliam et al., 2009; Gilliam et al., 2013; Gilliam, Moylan, Callahan,
Sumandea, & Reid, 2011). Previous research has demonstrated the beneficial influence of
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endurance exercise preconditioning in mitigating the negative cardio- and myotoxic
consequences of DOX treatment (Ascensão, Oliveira, & Magalhães, 2012; Chicco,
Schneider, & Hayward, 2006; Hayward, Lien, Jensen, Hydock, & Schneider, 2012;
Hydock, Lien, Jensen, Schneider, & Hayward, 2011b).
Skeletal muscle comprises a large part of the human body and is responsible for
posture and locomotion. It is unique in its plasticity to alter its form following various
stimuli. In adult muscle, myogenic regulatory factors (MRFs) guide satellite cells to
restore muscle integrity in response to damage and stress, such as exercise. Activated
satellite cells, expressing primary MRFs, form myoblasts, and differentiate into myotubes
in response to secondary MRFs and reconstitute muscle fibers. The ability of skeletal
muscle to repair itself and retain structure relies heavily on functional MRF proteins.
In vitro DOX exposure has been shown to decrease the ability of myoblasts to
differentiate into myotubes (Kurabayashi, Jeyaseelan, & Kedes, 1993). Additionally,
MRF mRNA expression is compromised under the same conditions with an up-regulation
of the MRF inhibitor, Id (Kurabayashi, Jeyaseelan, & Kedes, 1994). DOX has been
shown to induce oxidative stress, leading to cellular damage and single-stranded DNA
breaks. Beyond oxidative damage, genotoxic stress attributed to DOX leads to doublestranded DNA breaks. The primary MRF, MyoD, is fundamentally involved in myoblast
DNA repair (Kobayashi, Antoccia, Tauchi, Matsuura, & Komatsu, 2004). Its presence,
along with the other MRFs, is critical for skeletal muscle regeneration following
chemotherapy treatment which includes DOX. Prior endurance exercise training may also
influence the expression of MRFs in skeletal muscle. Following endurance training, SOL
of rats express elevated levels of oxidative enzyme genes and myogenin (Siu, Donley,
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Bryner, & Alway, 2004). Although MRF mRNA has been broadly investigated, protein
expression has been less examined.
The purpose of this study was to test whether a two-week treadmill protocol prior to
acute DOX administration would preserve skeletal muscle function (twitch force and
fatigue resistance) and decrease levels of lipid peroxidation. It was hypothesized that
DOX treatment would impair skeletal muscle force production and fatigue resistantce
while increasing lipid peroxidation. These decrements were predicted to be attenuated
with short-term aerobic preconditioning. In combination with elevated antioxidant
enzymes with short-term aerobic exercise, increased MRF protein may effectively
mitigate the skeletal muscle dysfunction attributed to DOX treatment and enhance
subsequent repairs. A tertiary hypothesis of this study postulated that exercise training
would elevate MRF concentrations in the SOL and EDL.
Materials and Methods
Experimental Design
Ten week old male Sprague-Dawley rats (Harlan: Indianapolis, IN; N=47) were
housed in pairs under a 12:12 hour light-dark cycle at room temperature (20 ± 2°C). Rats
were provided food (Harlan Taklad 2026 rat chow) and distilled water ad libitum. All
experimental procedures were approved by the University of Northern Colorado
Institutional Animal Care and Use Committee (Protocol #1407C-DH-R-17) and were in
compliance with the Animal Welfare Act guidelines.
Rats were randomly assigned to sedentary (SED) (n=20) or treadmill exercise
(EXER) (n=27) groups. The SED group was limited to normal cage activity for the
duration of the study. Animals in the EXER group were exercised progressively on a
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motorized treadmill at 30 m/min through week 1 and for one hour during week 2 (Table
5.1). When necessary, rats were motivated by light electric shock at the rear of treadmill
lanes. All EXER subjects completed the training protocol.

Table 5.1
Treadmill exercise training protocol
Day
1
2

3

4

5

6–7

8 - 12

Speed (m/min)

30

30

30

30

30

(Rest)

30

Duration (min)

10

20

30

40

50

(Rest)

60

Incline (%)

0

0

0

0

0

(Rest)

0

Drug Treatment
At the completion of the two week activity period, animals were sedentary for 24
hours. After the 24 hour sedentary period, animals were subdivided to receive DOX or
saline (SAL) injections: SED-SAL (n=10), SED-DOX (n=10), EXER-SAL (n=13),
EXER-DOX (n=14). Subjects in the DOX group received a bolus i.p. 15 mg/kg injection
of DOX hydrochloride (Bedford Labs: Bedford, OH). Animals in the SAL group received
an equivalent volume of 0.9% saline. 24 hours following injections, animals were
sacrificed and muscles of interest were removed.
Tissue Preparation
Animals were anesthetized with sodium pentobarbital (50 mg/kg), and once a tail
pinch reflex was absent, soleus (SOL) and extensor digitorum longus (EDL) muscles
were excised. Muscles from the left leg were flash frozen in liquid nitrogen and stored at
-80°C for later biochemical analysis. Muscles from the right leg were transferred to a
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warm organ bath (Radnoti: Monrovia, CA) of Krebs Henseleit buffer (120 NaCl, 5.9
KCl, 2.5 CaCl2, 1.2 MgCl, 25 NaHCO3, 17 glucose; in mM) for muscle function data
collection.
Assessment of Skeletal Muscle Function
Functional muscle data were obtained via electrostimulation of tissues. Two
electrodes surrounding the muscle in organ baths provided stimulation. Muscle
contraction forces were recorded using PowerLab data acquisition hardware
(ADInstruments: Colorado Springs, CO). Maximal twitch force was achieved by
adjusting muscle for optimal length, and subsequent change in voltage applied (Grass
Technologies: Warwick, RI).
The muscle stimulation methods follow the protocol reported by Hydock et al.
(2011). Muscles were allowed to stabilize in a warmed (37°C) and oxygenated (95%
O2/5% CO2) organ bath prior to functional experiments. Initial muscle tension was
adjusted to 0.5g, and stimulated with a square-wave pulse duration of 0.5 ms at 40V.
Muscle tension was increased by 0.2g per stimulation (2-minute rest) until twitch force
reached a maximum. Next, optimal voltage was verified by increasing applied voltage by
5V, allowing the same 2-minute rest period. Once maximal twitch force was determined,
the bath of Krebs-Henseleit buffer was cycled to ensure proper electrolyte balance for the
ensuing fatigue recording. The muscle was allowed a recovery time of 30 minutes in
fresh buffer before continuous stimulation cycling. Pulse duration was increased to 500
ms while maintaining the determined optimal length and voltage. The muscle was
stimulated continuously every 1 second for 2 minutes to simulate fatiguing conditions
(Hydock, Lien, Jensen, Schneider, & Hayward, 2011a). LabChart software
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(ADInstruments) was used to analyze force data acquired.
Measures of maximal force, maximal rate of force development, and maximal rate
of force decline were recorded during the single twitch force stimulation recordings.
During the continuous, fatiguing protocol, force production was recorded in reference to
baseline levels every 10 seconds, for a total of 100 seconds.
Biochemical Analysis
Flash frozen left hindlimb muscles were homogenized and sonicated in
radioimmunoprecipitation assay (RIPA) buffer (10:1) and protease enzyme inhibitors
(SigmaAldrich: St. Louis, MO). Homogenates were then spun in a microcentrifuge for 10
minutes at 3000g at 4°C. Total protein was quantified and standardized in samples
according to the bicinchronic acid (BCA) assay (Smith et al., 1985).
Lipid Peroxidation
The most abundant product of LPO is malondialdehyde (MDA), and it is
commonly assayed as an index of oxidative stress. LPO was determined using a
commercially available assay kit (BioxyTech MDA-586, Oxis Research: Foster City,
CA). Malondialdehyde and 4-hydroxyalkenals (MDA+4-HAE) were measured to
indicate cellular lipid peroxidation. Two hundred µL of sample homogenate was added to
a microcentrifuge tube. Six hundred-fifty µL of N-methyl-2-phenylindole in acetonitrile
was added to the sample and briefly vortexed. One hundred-fifty µL of methanesulfonic
acid was then be added and vortexed, followed by a 60 minute incubation period at 45°C.
Following the incubation period, samples were centrifuged at 10,000g for 10 minutes to
remove turbidity. Supernatants were then transferred to cuvettes for absorbency
measurement using a spectrophotometer at 586 nm. Concentration of MDA+4-HAE was
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estimated from a standard curve. Samples were run in duplicate and reassayed if samples
varied by more than 5%.
Western Blotting
Western blot analysis was conducted on muscle samples for the presence of
MRFs in the SOL and EDL. An equal volume of Lammeli buffer was added to samples,
and samples were heated in boiling water for 2 minutes, then chilled on ice for 5 minutes
before 46 µg of protein was loaded onto 4-20% gradient Tris-Glycine NuPage precast
gels (LifeTechnologies: Carlsbad, CA). Gels were run at 125 constant voltage and 4 mA
current for 2 hours in a Xcell II blot module (Invitrogen, LifeTechnologies). Proteins
were transferred to 0.45 micron polyvinylidene fluoride (PVDF) membranes over 90
minutes at 25 volts and 100 mA. Band transfers to PVDF membranes were ensured by
the presence of a SeeBlue® Plus2 protein ladder (Novex, LifeTechnologies). Membranes
were blocked for 1 hour in 15 mL of TBST + 5% milk, and then incubated with gentle
agitation overnight in 10 mL of primary antibodies. Membranes were then washed in
TBST three times for 5 minutes, followed by incubation in appropriate species-specific
secondary antibodies for 1 hour. After three more 5-minute washes in TBST, membranes
were prepared for protein band detection.
Detection was executed by enhanced chemiluminescence (ECL) (C-Digit, Li-Cor:
Lincoln, NE), and ImageJ software (NIH: Bethesda, MD) was used to quantify the
protein bands. Immediately before chemiluminescent imaging, 1.5 mL of luminol and
enhancer (SuperSignal West Femto Maximum Sensitivity Chemiluminescent Substrate,
ThermoScientific: Waltham, MA) was added to the membrane. The primary antibodies of
interest included rabbit monoclonal MyoD, myogenin (Santa Cruz Biotechnology:
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Dallas, TX), Myf5, and Mrf4 (Abcam: Cambridge, MA). The rabbit monoclonal antiGAPDH (Abcam) was used as a loading control. Molecular weights of protein bands
were ensured in reference to a MagicMark™ XP standard ladder (Novex,
LifeTechnologies). Secondary antibodies (Santa Cruz Biotechnology) corresponded to
associated species (rabbit) and include horseradish peroxidase (HRP) for adequate
reactivity.
Statistical Analysis
Data were analyzed and presented using GraphPad Prism statistical software
(GraphPad: LaJolla, CA). Variables analyzed were assessed as means ± standard error
(mean±SE). A two-factor (Exercise X Drug) analysis of variance (ANOVA) was used to
determine main effects and interactions of treatments in muscle mass, muscle force
production, lipid peroxidation, and MRF concentration. If a significant F-value was
observed, a Tukey post-hoc pair-wise comparison identified significant differences
between groups. Variables included the four MRF proteins concentrations, muscle
masses, and force parameters from ex vivo analysis in each of the groups (maximal
twitch, maximal rate of force production, and maximal rate of force decline). Muscle
fatigue responses were analyzed with maximal twitch force obtained every 10 seconds,
and compared to baseline twitch force (0 sec). Fatigue was determined to be when force
production fell below 75% of baseline values. For all procedures, significance was set at
the α=0.05 level.
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Results
General Observations
Table 5.2 presents animal characteristics at the time of injection and at the time of
sacrifice. At the time of injection, animal body mass was significantly different between
groups. An activity effect was observed with SED animals exhibiting significantly greater
body mass, F (1, 43) = 16.72, p<0.05. Post hoc testing revealed body mass to be higher in
SED-SAL and SED-DOX than EXER-SAL, p<0.05.

Table 5.2
Animal Characteristics.
SED-SAL

SED-DOX

EXER-SAL

EXER-DOX

Injection Mass (g) 359.5 ± 11.3 a 364.4 ± 9.9 a 322.1 ± 5.2

335.0 ± 6.8

Sacrifice Mass (g) 360.4 ± 11.9 b 353.9 ± 9.0 b 325.5 ± 6.3

328.5 ± 6.1

SOL Mass (mg)

134.9 ± 6.6

140.4 ± 4.4

131.5 ± 5.1

132.9 ± 4.6

EDL Mass (mg)

142.0 ± 4.8

138.3 ± 7.6

135.2 ± 3.6

140.9 ± 3.6

SED-SAL = sedentary saline, n=10; SED-DOX = sedentary doxorubicin, n=10; EXERSAL = exercise saline, n=13; EXER-DOX = exercise doxorubicin, n=14. Values are
means ± SEM.
a
= Significantly greater than EXER-SAL (p<0.05).
b
= Significantly greater than EXER-DOX (p<0.05).
Significant activity effect in injection and sacrifice body mass (p<0.05).
At the time of sacrifice, a similar activity effect existed with greater mass in SED
animals, F (1, 43) = 13.42, p<0.05. Post hoc testing revealed that EXER-DOX body mass
was significantly less than SED-SAL and SED-DOX, p<0.05. A significant drug effect
was observed in body mass change as well, F (1.43) = 34.65, p<0.05 (Figure 5.1). Rats
receiving SAL slightly gained body mass after injections (1%) while those receiving
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DOX decreased body mass (2.5%). Within groups, body mass changes were not
significantly different (p>0.05). Reductions in body mass of DOX-treated animals may
be attributed to significantly less food intake within 24 hour following injections (Gilliam
et al., 2009).
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Figure 5.1. Change in body mass following injections.
SED-SAL = sedentary saline, n=10; SED-DOX = sedentary doxorubicin, n=10; EXERSAL = exercise saline, n=13; EXER-DOX = exercise doxorubicin, n=14. Values are
mean ± SEM.
a
= Significantly different from EXER-SAL (p<0.05).
b
= Significantly different from SED-SAL (p<0.05).
There was no significant difference in absolute SOL mass observed between
groups, p>0.05 (Figure 5.2A). Similarly, when SOL mass was corrected for body mass,
no significant difference was detected, p>0.05 (Table 5.3, Figure 5.3A). Absolute EDL
masses displayed no significant differences for main effects or exercise by drug
interaction, p<0.05 (Figure 5.2B). When corrected for body mass, an activity effect was
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detected with endurance-trained animals demonstrating higher relative EDL mass, F = (1,
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43) = 4.871, p<0.05 (Figure 5.3B).

Figure 5.2. Tissue mass at time of sacrifice, SOL (A) and EDL (B).
SOL = soleus, EDL = extensor digitorum longus, SED-SAL = sedentary saline, n=10;
SED-DOX = sedentary doxorubicin, n=10; EXER-SAL = exercise saline, n=13; EXERDOX = exercise doxorubicin, n=14. Values are mean ± SEM.
Table 5.3
Tissue mass relative to body mass.
SED-SAL

SED-DOX

EXER-SAL

EXER-DOX

SOL (mg/g BM)

0.37 ± 0.01

0.39 ± 0.01

0.40 ± 0.01

0.41 ± 0.01

EDL (mg/g BM)

0.39 ± 0.01

0.39 ± 0.02

0.42 ± 0.01

0.43 ± 0.01

SOL = soleus, EDL = extensor digitorum longus, SED-SAL = sedentary saline, n=10;
SED-DOX = sedentary doxorubicin, n=10; EXER-SAL = exercise saline, n=13; EXERDOX = exercise doxorubicin, n=14. Values are mean ± SEM.
a
= Significantly different from EXER-SAL (p<0.05).
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Figure 5.3. Tissue mass relative to body mass, SOL (A) and EDL (B).
SOL = soleus, EDL = extensor digitorum longus, BM = body mass, SED-SAL =
sedentary saline, n=10; SED-DOX = sedentary doxorubicin, n=10; EXER-SAL =
exercise saline, n=13; EXER-DOX = exercise doxorubicin, n=14. Values are mean ±
SEM.
Isolated Muscle Function
Maximal Twitch Force. Once right SOL and EDL were excised, muscles were
placed in organ baths filled with Krebs-Henseleit buffer. Tension and voltage were
gradually increased to determine optimum conditions as detected by maximal twitch
force elicited. Additionally, maximal rate of force production and maximal rate of force
decline were measured from maximal twitch force tracings.
No significant differences were observed in SOL maximal twitch forces between
groups, p>0.05 (Table 5.4). After adjusting force relative to tissue mass, significance
remained undetected (Figure 5.4). Rates of force production and decline were also not
significantly different between groups, p<0.05.
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Table 5.4
SOL muscle twitch forces
SED-SAL
Maximal Twitch
Force (mN)

37 ± 3

SED-DOX
50 ± 5

EXER-SAL

EXER-DOX

44 ± 4

46 ± 4

Relative Maximal
249 ± 36
287 ± 29
258 ± 28
296 ± 41
Twitch Force
(mN/g)
Maximal Rate of
4916 ± 463
6376 ± 699
5478 ± 670
5536 ± 589
Force Production
(mN/s)
Maximal Rate of
- 1715 ± 193 - 1935 ± 160
- 2027 ± 117 - 2255 ± 154
Force Decline
(mN/s)
SOL = soleus, SED-SAL = sedentary saline, n=10; SED-DOX = sedentary doxorubicin,
n=10; EXER-SAL = exercise saline, n=13; EXER-DOX = exercise doxorubicin, n=14.
Values are mean ± SEM.
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Figure 5.4. SOL Maximal twitch force values. Maximal twitch (A), maximal twitch
relative to tissue mass (B), rate of force production (C), rate of force production (D), SOL
rate of force decline.
SOL = soleus, SED-SAL = sedentary saline, n=10; SED-DOX = sedentary doxorubicin,
n=10; EXER-SAL = exercise saline, n=13; EXER-DOX = exercise doxorubicin, n=14.
Values are mean ± SEM.
No significant differences were seen between groups in EDL maximal twitch
forces, p>0.05 (Table 5.5). Similarly, no significance was observed after correcting for
tissue mass. Rates of force production and decline were not significantly different
between groups, as well (Figure 5.5).
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Table 5.5
EDL muscle twitch forces
SED-SAL
Maximal Twitch
Force (mN)

79 ± 7

SED-DOX
90 ± 9

EXER-SAL

EXER-DOX

92 ± 8

77 ± 12

Relative Maximal
511 ± 26
603 ± 69
632 ± 51
545 ± 80
Twitch Force
(mN/g)
Maximal Rate of
14407 ± 1199 17851 ± 2060
18242 ± 1772 14966 ± 2603
Force Production
(mN/s)
Maximal Rate of
- 8489 ± 690
- 10410 ± 1155 - 11583 ± 1272 - 9308 ± 1380
Force Decline
(mN/s)
EDL = extensor digitorum longus, SED-SAL = sedentary saline, n=10; SED-DOX =
sedentary doxorubicin, n=10; EXER-SAL = exercise saline, n=13; EXER-DOX =
exercise doxorubicin, n=14. Values are mean ± SEM.
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Figure 5.5. EDL Maximal twitch force values. Maximal twitch (A), maximal twitch
relative to tissue mass (B), rate of force production (C), rate of force production (D), SOL
rate of force decline.
EDL = extensor digitorum longus, SED-SAL = sedentary saline, n=10; SED-DOX =
sedentary doxorubicin, n=10; EXER-SAL = exercise saline, n=13; EXER-DOX =
exercise doxorubicin, n=14. Values are mean ± SEM.
Fatigue. After cycling Krebs-Henseleit buffer and allowing muscles to rest for 30
minutes, a 2-minute continuous stimulation at determined optimal length and voltage was
performed. Time-to-fatigue was determined when muscles produced 75% of baseline
force production.
In the SOL, SED-DOX and EXER-SAL generated less than 75% baseline force
40 seconds into fatiguing protocol. At the 50-second time point, EXER-DOX force
production was below 75%. SED-SAL recorded the greatest fatigue resistance with
twitch forces lower than 75% of baseline by 70 seconds (Figure 5.6).

83

100
95

Percentage Force (%)

90
85
80
75
70
65
60
55

10
0

90

80

70

60

50

40

30

20

10

0

50

Time (sec)
SED-SAL

SED-DOX

EXER-SAL

EXER-DOX

Figure 5.6. SOL fatigue resistance.
SOL = soleus, SED-SAL = sedentary saline, n=10; SED-DOX = sedentary doxorubicin,
n=10; EXER-SAL = exercise saline, n=13; EXER-DOX = exercise doxorubicin, n=14.
Values are means ± SEM.
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In the EDL, SED-SAL fatigued quickest with twitch forces less than 75% at the
40-second time point. SED-DOX, EXER-SAL, and EXER-DOX groups’ forces fell
below fatigue threshold at 50 seconds (Figure 5.7). The fast-twitch muscle typically
fatigues a greater rate than slow, oxidative muscles. Ex vivo force production of the EDL
did not fatigue faster to levels below 75% of initial force values but, at the end 100
seconds, all groups’ twitch forces were below those of the SOL.
The short-term duration of training may not have been long enough to
accommodate appreciable fatigue resistance in SOL of EXER animals receiving DOX.
Additionally, with greater time passing after DOX treatment functional deficits are
evident. The 24 hours following injection may not have been enough to elucidate effects.
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Figure 5.7. EDL fatigue resistance.
EDL = extensor digitorum longus, SED-SAL = sedentary saline, n=10; SED-DOX =
sedentary doxorubicin, n=10; EXER-SAL = exercise saline, n=13; EXER-DOX =
exercise doxorubicin, n=14. Values are means ± SEM.
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Biochemical Analyses
Lipid Peroxidation. SOL and EDL homogenates obtained from rats 1 day after
saline or DOX injection were analyzed for markers of lipid peroxidation (MDA+4-HAE).
All data from LPO analysis are presented in Table 5.6. In SOL, a significant drug effect
was observed. Rats receiving SAL exhibited higher levels of MDA+4-HAE than DOX
animals, F = (1, 43), p<0.05 (Figure 5.8A). Post hoc analyses identified EXER-SAL
animals to express significantly greater indices of lipid peroxidation than SED-DOX and
EXER-DOX. No activity effect or interaction was detected in the SOL. In the EDL, a
significant activity effect was observed with TM animals presenting higher MDA+4HAE, F = (1, 43) = 4.08, p<0.05 (Figure 5.8B). No drug effect or interaction was
detected. The activity effect seen in EDL of EXER animals may have been due to stress
of treadmill training on largely glycolytic muscles.

Table 5.6
Lipid peroxidation levels
SED-SAL

SED-DOX

EXER-SAL

EXER-DOX

SOL (pmol/mg)

329 ± 24

275 ± 17 a

398 ± 36

292 ± 17 a

EDL (pmol/mg)

214 ± 14

225 ± 17

283 ± 28

288 ± 44

SOL = soleus, EDL = extensor digitorum longus, SED-SAL = sedentary saline, n=10;
SED-DOX = sedentary doxorubicin, n=10; EXER-SAL = exercise saline, n=13; EXERDOX = exercise doxorubicin, n=14. Values are mean ± SEM.
a
= Significantly different from EXER-SAL (p<0.05).
Significant drug effect in the SOL (p<0.05).
Significant activity effect in the EDL (p<0.05).
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Figure 5.8. Lipid peroxidation levels in hindlimb muscles, SOL (A) and EDL (B).
SOL = soleus, EDL = extensor digitorum longus, SED-SAL = sedentary saline, n=10;
SED-DOX = sedentary doxorubicin, n=10; EXER-SAL = exercise saline, n=13; EXERDOX = exercise doxorubicin, n=14. Values are mean ± SEM.
a
= Significantly different from EXER-SAL.
Significant drug effect in SOL (p<0.05).
Significant activity effect in EDL (p<0.05).
Western Blotting. Expression of myogenic regulatory factor proteins, Myf5,
MyoD, Mrf4, and myogenin, were measured in SOL and EDL homogenates to evaluate
the influence of endurance exercise and DOX on these transcription factors. Forty-six µg
protein from SOL and EDL homogenates were added to 4-20% Tris-glycine precast gels
and run through SDS-PAGE. MRF levels were assessed by chemiluminescence and
expressed relative to GAPDH as a loading control. It should be noted that no significant
GAPDH activity and drug main effects or interactions (p>0.05) were observed suggesting
that the exercise or drug treatments did not affect the loading control. All Western blot
data are presented in Tables 5.7 (SOL) and 5.8 (EDL).
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Table 5.7
SOL MRF levels
SED-SAL
Myogenic Factor 5
(Myf5)
MyoD
Myogenin

SED-DOX

EXER-SAL

EXER-DOX

0.44 ± 0.10 a 0.73 ± 0.14

0.92 ± 0.08

1.28 ± 0.22

1.29 ± 0.13

1.67 ± 0.13

1.46 ± 0.16

2.11 ± 0.31

0.50 ± 0.12

0.67 ± 0.14

0.81 ± 0.17

0.80 ± 0.16

Muscle Regulatory
0.62 ± 0.18 0.80 ± 0.20
1.23 ± 0.18
1.22 ± 0.24
Factor 4 (Mrf4)
SOL = soleus, SED-SAL = sedentary saline, n=10; SED-DOX = sedentary doxorubicin,
n=10; EXER-SAL = exercise saline, n=13; EXER-DOX = exercise doxorubicin, n=14.
Values are mean ± SEM.
a
= Significantly different from EXER-DOX (p<0.05).
Significant activity and drug effect in Myf5 (p<0.05).
Significant drug effect in MyoD (p<0.05).
Significant effect effect in Mrf4 (p<0.05).
Table 5.8
EDL MRF levels
SED-SAL

SED-DOX

EXER-SAL

EXER-DOX

Myogenic Factor 5
(Myf5)

1.25 ± 0.23

1.25 ± 0.19

1.57 ± 0.19

1.49 ± 0.14

MyoD

1.28 ± 0.20

1.55 ± 0.17

1.30 ± 0.07

1.13 ± 0.09

Myogenin

0.48 ± 0.15

0.64 ± 0.15

0.62 ± 0.11

0.67 ± 0.14

Muscle Regulatory
0.47 ± 0.12
0.52 ± 0.13
0.64 ± 0.09
0.46 ± 0.08
Factor 4 (Mrf4)
EDL = extensor digitorum longus, SED-SAL = sedentary saline, n=10; SED-DOX =
sedentary doxorubicin, n=10; EXER-SAL = exercise saline, n=13; EXER-DOX =
exercise doxorubicin, n=14. Values are mean ± SEM.

89
Myogenic Factor 5. In the SOL, a 2-way ANOVA revealed a significant activity
effect, with EXER groups exhibiting higher levels of myogenic factor 5 (Myf5), F (1, 43)
= 10.42, p<0.05 (Figure 5.9A). Additionally, a drug effect was observed, with DOXtreated groups expressing higher Myf5, F (1, 43) = 4.267, p=<0.05. No significant
interaction was observed. Post hoc tests revealed that SED-SAL expressed significantly
less Myf5 than EXER-DOX.
In the EDL, no significant main effects were observed (Figure 5.9B). No
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interaction was seen in the EDL, and no interaction was detected.

Figure 5.9. Myf5 expression levels, SOL (A) and EDL (B).
SOL = soleus, EDL = extensor digitorum longus, OD = optical density, SED-SAL =
sedentary saline, n=10; SED-DOX = sedentary doxorubicin, n=10; EXER-SAL =
exercise saline, n=13; EXER-DOX = exercise doxorubicin, n=14. Values are mean ±
SEM.
a
= Significantly different from EXER-DOX.
Significant activity and drug effect in SOL Myf5 (p<0.05).

90
MyoD. In the SOL, a significant drug effect was observed, with DOX groups
exhibiting higher levels of MyoD, F (1, 43) = 5.382, p<0.05 (Figure 5.10A). No activity
effect and no interaction in SOL MyoD were detected. In the EDL, no significant main
effects were identified. and no interaction was observed (Figure 5.10B).
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Figure 5.10. MyoD expression levels, SOL (A) and EDL (B).
SOL = soleus, EDL = extensor digitorum longus, OD = optical density, SED-SAL =
sedentary saline, n=10; SED-DOX = sedentary doxorubicin, n=10; EXER-SAL =
exercise saline, n=13; EXER-DOX = exercise doxorubicin, n=14. Values are mean ±
SEM.
Significant drug effect in SOL MyoD (p<0.05).
Myogenin. In the SOL, no significant drug or activity effects were observed
(Figure 5.11A). In the EDL, no significant main effects or interaction were identified
(Figure 5.11B).
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Figure 5.11. Myogenin expression levels, SOL (A) and EDL (B).
SOL = soleus, EDL = extensor digitorum longus, OD = optical density, SED-SAL =
sedentary saline, n=10; SED-DOX = sedentary doxorubicin, n=10; EXER-SAL =
exercise saline, n=13; EXER-DOX = exercise doxorubicin, n=14. Values are mean ±
SEM.
Muscle Regulatory Factor 4. In the SOL, a significant activity effect was
observed, with EXER groups exhibiting higher levels of muscle regulatory factor 4
(Mrf4), F (1, 43) = 5.672, p=0.0217 (Figure 5.12A). No drug effect or interaction in the
SOL was detected. In the EDL, no significant main effects were identified, and no
interaction was observed either (Figure 5.12B).
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Figure 5.12. Mrf4 expression levels, SOL (A) and EDL (B).
SOL = soleus, EDL = extensor digitorum longus, OD = optical density, SED-SAL =
sedentary saline, n=10; SED-DOX = sedentary doxorubicin, n=10; EXER-SAL =
exercise saline, n=13; EXER-DOX = exercise doxorubicin, n=14. Values are mean ±
SEM.
Significant activity effect in SOL Mrf4 (p<0.05).
Discussion
This is the first study to assess endurance exercise training and in vivo DOX
effects on MRF expression in skeletal muscle. It was hypothesized that a two-week
treadmill protocol prior to acute DOX administration would preserve muscle twitch
forces and fatigue resistance, decrease levels of lipid peroxidation, and enhance MRF
concentrations. The major findings are that 1) exercise did not alter muscle force
parameters, 2) LPO was elevated in SAL-treated SOL and EXER group EDL, and 3)
exercise training elevated Myf5 and Mrf4 levels in the SOL and acute DOX treatment
increased Myf5 and MyoD in the SOL.
EXER animals had lower body masses than SED animals after two weeks of
treadmill exercise, which may be attributed to increased caloric expenditure. Absolute
and relative muscle tissue masses were not significantly reduced in DOX-treated groups
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compared with acute SAL treatment. Previous studies identify DOX-induced decreases in
muscle mass, but these losses are typically seen after 3 days (Doroshow et al., 1985).
Within group body masses did not significantly differ, which is consistent with similar
studies involving acute DOX exposure (Wonders, Hydock, Schneider, & Hayward,
2008).
Regarding skeletal muscle function, no significant differences were observed in
either SOL or EDL as measures of ex vivo maximal twitch force. The present data
suggest that acute DOX treatment did not reduce force production in hindlimb muscles
one day following DOX injection. SED-DOX groups trended toward slightly better
performance than SED-SAL in all maximal twitch measures (max force, rate of force
development, rate of force decline). Previous studies have shown Ca2+ release to increase
without changing Ca2+ sensitivity in muscle fibers exposed to DOX (Chugun et al., 2000;
Zorzato, Salviati, Facchinetti, & Volpe, 1985). Failure of SR reuptake of Ca2+ may
increase force produced during contractions, which may explain the trend toward slightly
higher SED-DOX muscle twitch forces compared to SED-SAL (MacLennan, 2000).
Although two weeks of endurance exercise in SAL animals trended toward
slightly higher force production, variables were not significantly different. DOX groups
showed no significant differences in force production due to exercise preconditioning. In
the SOL, SED-SAL took longest to fatigue below 75% of baseline force (70 sec), while
SED-DOX and EXER-SAL fatigued quickest (40 sec). Conversely, the EDL of SEDSAL animals produced forces below the fatigue point (75%) ten seconds before all other
groups (40 vs 50 sec). A study employing an equivalent dosage by Hydock et al. (2011)
demonstrated significantly less twitch force, maximal rate of force production, and
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maximal rate of force decline in DOX-treated animals five days following injections. The
time period following DOX administration in this study may have been too brief to
induce significant functional deficits. Additionally, exercise-induced injury of skeletal
muscle without adequate time for recovery may explain EXER-SAL decrements in
fatigue resistance of SOL. A previous study examining skeletal muscle damage
associated with running reported degeneration, necrosis and phagocytosis shortly after
and during 2 weeks following the onset of exercise (Irintchev & Wernig, 1987).
The generation of reactive oxygen species has been implicated as a mechanism of
DOX’s antineoplastic actions (Minotti, Menna, Salvatorelli, Cairo, & Gianni, 2004). As a
side effect of DOX treatment, uncontrolled ROS production can induce LPO, damage to
cell membranes and organelles, disrupted signaling pathways, apoptosis, and muscle
atrophy (Chance, Sies, & Boveris, 1979). Additionally, ROS have been shown to
stimulate Ca2+ release from skeletal muscle SR and affect the regulation of K+ channels
in muscle tissues (Favero, Zable, & Abramson, 1995; Hool, Di Maria, Viola, & Arthur,
2005; Tang, Santarelli, Heinemann, & Hoshi, 2004). Interestingly, LPO levels in the SOL
indicated a drug effect, with SAL groups presenting higher levels of MDA + 4-HAE. The
predominantly fast, glycolytic EDL of EXER groups exhibited greater levels of lipid
peroxidation than SED, which may be expected due to increased oxidative activity with
treadmill running. ROS production signals pathways to promote skeletal muscle
adaptations following exercise (Franco, Odom, & Rando, 1999; Li, Chen, Li, & Reid,
2003). If training periods were extended, a significant increase in SOL MDA+4-HAE
content with exercise may have also been observed as a previous study by Liu et al.
(2000) demonstrated both fast and slow muscle MDA content to be elevated following
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chronic treadmill training in rats versus sedentary and acutely-trained animals. Human
and rat studies suggest repeated exercise induces increased antioxidant levels and enzyme
activity, which handle free radicals and reduce lipid peroxidation (Dekkers, Van Dooren,
& Kemper, 1996). DOX administration did not elevate levels of MDA + 4-HAE at one
day post-injection. The acute time point following injections (1 day) may not have
allowed for significant DOX-associated lipid peroxidation of cell membranes to occur.
Expression of MRFs is required for the regeneration of muscle fibers in response
to trauma or injury. These proteins direct satellite cells for myogenic lineage and
differentiation into formed myotubes. In this study, MRFs were typically elevated in the
SOL of DOX animals that performed endurance exercise compared to sedentary
counterparts. Significant main activity effects were detected in Myf5 and Mrf4 with
treadmill training. Myf5 may be critical to reestablish satellite cells for skeletal muscle
regeneration following bouts of chemotherapy, and reducing muscle mass losses. The
main activity effect was observed in DOX-treated rats that exercise trained as they
expressed 75% more Myf5 than their SED counterparts. Additionally, EXER-SAL rats
expressed 109% more Myf5 than SED-SAL.
A main activity effect was seen with increased Mrf4 expression following
treadmill training. EXER-DOX expressed 51% more Mrf4 than SED-DOX. EXER-SAL
rats expressed 99% more Mrf4 than SED-SAL. Increased Mrf4 expression may assist in
terminal differentiation of new muscle cells. Additionally, Mrf4 has been shown to act
upstream of MyoD determining cells for muscle identity (Kassar-Duchossoy et al., 2004).
Taken together, exercise-induced elevations of these two MRFs (Myf5, Mrf4) posit the
potential for greater muscle regeneration following DOX treatment versus sedentary
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controls. Although not significant, EXER-DOX trended toward greater concentrations of
MyoD and myogenin versus SED-DOX (27% and 20%, respectively).
Given the modality of endurance training, it is understandable that significant
MRF alterations were observed in the slow, oxidative SOL versus the fast, glycolytic
EDL. With running exercise, greater stress is placed on oxidative hindlimb muscles.
Irintchev and Wernig (1987) indicated that voluntary running of mice induces damage in
the SOL and tibialis anterior muscles, but not the EDL.
No main effects or interaction were observed in EDL. However, Myf5 and
myogenin trended to slightly higher expression in EXER-DOX than SED-DOX groups
(19% and 5%, respectively). In this study, overall MyoD levels were expressed at greater
concentrations in the SOL than in the EDL (19%). Previous studies show higher MyoD
mRNA levels in fast, glycolytic muscles (Hughes, Koishi, Rudnicki, & Maggs, 1997).
The results of the present study may suggest that despite higher MyoD mRNA in Type II
muscles, expression of the MyoD at the protein level may be higher in Type I fibers.
Additionally, in vitro studies indicate a depression in MyoD when exposed to DOX
(Kurabayashi et al., 1993, 1994). Conversely, our results present a drug effect with
increased levels of MyoD expression in the SOL following DOX injections.
At time points greater than 24 hours following DOX treatment, reductions in
MRF expression may occur as mass and function decrease but, the increased levels of
Myf5 and Mrf4 may alleviate such losses. Along with CD34 and M-cadherin, Myf5
define quiescent satellite cells commited to myogenesis (Beauchamp et al., 2000).
Decreased Myf5 expression in cultured cells is marked by decreased proliferation of
satellite cell-derived myoblasts and delayed differentiation of myotubes (Ustanina,
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Carvajal, Rigby, & Braun, 2007). Given the expression of Mrf4 at the time around and
after fusion, elevated protein levels suggest increased skeletal muscle repair (Zhou &
Bornemann, 2001). Endurance exercise-induced increases in Myf5 and Mrf4 potentially
improve satellite cell populations and fusion of myotubes thereby attenuating muscle
mass losses in the SOL after acute DOX treatment.
Conclusion
The present study examined the effects of short-term endurance exercise and
acute DOX administration on skeletal muscle force production, fatigue resistance, LPO,
and expression of MRFs. Although no remarkable findings were observed in muscle
function or lipid peroxidation, a significant elevation in the expression of Myf5 and Mrf4
with endurance training in the SOL was revealed. Myf5 is suggested to replenish satellite
cell pools and Mrf4 assists in the terminal differentiation of muscle cells (Rudnicki et al.
2008; Zhu & Miller, 1997). With increases in these two MRFs, the ability to regenerate
and repair skeletal muscle may be enhanced in the time following chemotherapy, when
loss in muscle mass is common. Future research examining parameters at later time
points following treatment may elicit differential effects, but endurance exercise shows
promise in upregulating some myogenic transcription factor expression (Myf5, Mrf4) in
slow, oxidative muscles shortly after acute DOX treatment. Given the importance of
time-to-chemotherapy and improved clinical outcomes, a short-term endurance exercise
protocol prior to treatment may provide a feasible measure to prevent muscle mass losses
seen with chemotherapy in cancer patients (de Melo Gagliato et al. 2014; Doroshow, et
al., 1985; Gilliam et al., 2009; Gilliam et al., 2013; Gilliam et al., 2011).

98

REFERENCES
Anderson, E. J., & Neufer, P. D. (2006). Type II skeletal myofibers possess unique
properties that potentiate mitochondrial H(2)O(2) generation. American Journal
of Physiology - Cell Physiology, 290(3), C844-851. doi:
10.1152/ajpcell.00402.2005
Ascensão, A., Oliveira, P. J., & Magalhães, J. (2012). Exercise as a beneficial adjunct
therapy during Doxorubicin treatment—Role of mitochondria in cardioprotection.
International Journal of Cardiology, 156(1), 4-10.
Azmi, S., Ozog, A., & Taneja, R. (2004). Sharp-1/DEC2 inhibits skeletal muscle
differentiation through repression of myogenic transcription factors. Journal of
Biological Chemistry, 279(50), 52643-52652.
Beauchamp, J. R., Heslop, L., Yu, D. S., Tajbakhsh, S., Kelly, R. G., Wernig, A.,
Buckingham, M. E., Partridge, T. A., & Zammit, P. S. (2000). Expression of
CD34 and Myf5 defines the majority of quiescent adult skeletal muscle satellite
cells. Journal of Cell Biology, 151(6), 1221-1234. Retrieved from
http://www.ncbi.nlm.nih.gov/pubmed/11121437
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2190588/pdf/0004041.pdf
Bagchi, D., Bagchi, M., Hassoun, E. A., Kelly, J., & Stohs, S. J. (1995). Adriamycininduced hepatic and myocardial lipid peroxidation and DNA damage, and
enhanced excretion of urinary lipid metabolites in rats. Toxicology, 95(1-3), 1-9.
Benezra, R., Davis, R. L., Lockshon, D., Turner, D. L., & Weintraub, H. (1990). The
protein Id: a negative regulator of helix-loop-helix DNA binding proteins. Cell,
61(1), 49-59. doi: http://dx.doi.org/10.1016/0092-8674(90)90214-Y
Bentzinger, C. F., Wang, Y. X., & Rudnicki, M. A. (2012). Building muscle: molecular
regulation of myogenesis. Cold Spring Harbor Perspectives in Biology, 4(2),
a008342. doi: 10.1101/cshperspect.a008342
Bickel, C. S., Slade, J., Mahoney, E., Haddad, F., Dudley, G. A., & Adams, G. R. (2005).
Time course of molecular responses of human skeletal muscle to acute bouts of
resistance exercise. Journal of Applied Physiology (1985), 98(2), 482-488. doi:
10.1152/japplphysiol.00895.2004

99
Biggs, J., Murphy, E. V., & Israel, M. A. (1992). A human Id-like helix-loop-helix
protein expressed during early development. Proceedings of the National
Academy of Sciences of the United States of America, 89(4), 1512-1516.
Bischoff, R. (1994). The satellite cell and muscle regeneration. Myology, 1, 97-118.
Black, B. L., & Olson, E. N. (1998). Transcriptional control of muscle development by
myocyte enhancer factor-2 (MEF2) proteins. Annual Review of Cell and
Developmental Biology, 14(1), 167-196. doi: 10.1146/annurev.cellbio.14.1.167
Bober, E., Lyons, G. E., Braun, T., Cossu, G., Buckingham, M., & Arnold, H. (1991).
The muscle regulatory gene, Myf-6, has a biphasic pattern of expression during
early mouse development. Journal of Cell Biology, 113(6), 1255-1265.
Bonifati, D. M., Ori, C., Rossi, C. R., Caira, S., Fanin, M., & Angelini, C. (2000).
Neuromuscular damage after hyperthermic isolated limb perfusion in patients
with melanoma or sarcoma treated with chemotherapeutic agents. Cancer
Chemotherapy and Pharmacology, 46(6), 517-522. doi: 10.1007/s002800000175
Brand-Saberi, B., & Christ, B. (1999). Genetic and epigenetic control of muscle
development in vertebrates. Cell and Tissue Research, 296(1), 199-212.
Braun, T., Rudnicki, M. A., Arnold, H.-H., & Jaenisch, R. (1992). Targeted inactivation
of the muscle regulatory gene Myf-5 results in abnormal rib development and
perinatal death. Cell, 71(3), 369-382.
Buckingham, M. (2001). Skeletal muscle formation in vertebrates. Current Opinion in
Genetics and Development, 11(4), 440-448.
Burckart, K., Beca, S., Urban, R. J., & Sheffield-Moore, M. (2010). Pathogenesis of
muscle wasting in cancer cachexia: targeted anabolic and anticatabolic therapies.
Current Opinion in Clinical Nutrition and Metabolic Care, 13(4), 410-416.
Chabner, B., Ryan, D., Paz-Ares, L., & Garcia-Carbonero, R. (2001). P. Calabresi in The
Pharmacological Basis of Therapeutics: McGraw Hill, NY.
Chance, B., Sies, H., & Boveris, A. (1979). Hydroperoxide metabolism in mammalian
organs. Physiological Reviews, 59(3), 527-605.
Chandra, J., Samali, A., & Orrenius, S. (2000). Triggering and modulation of apoptosis
by oxidative stress. Free Radical Biology and Medicine, 29(3-4), 323-333. doi:
http://dx.doi.org/10.1016/S0891-5849(00)00302-6
Chi, N., & Epstein, J. A. (2002). Getting your Pax straight: Pax proteins in development
and disease. Trends in Genetics, 18(1), 41-47.

100
Chicco, A. J., Hydock, D. S., Schneider, C. M., & Hayward, R. (2006). Low-intensity
exercise training during doxorubicin treatment protects against cardiotoxicity.
Journal of Applied Physiology (1985), 100(2), 519-527. doi:
10.1152/japplphysiol.00148.2005
Chicco, A. J., Schneider, C. M., & Hayward, R. (2006). Exercise training attenuates acute
doxorubicin-induced cardiac dysfunction. Journal of Cardiovascular
Pharmacology, 47(2), 182-189. doi: 10.1097/01.fjc.0000199682.43448.2d
Choi, J., Costa, M., Mermelstein, C., Chagas, C., Holtzer, S., & Holtzer, H. (1990).
MyoD converts primary dermal fibroblasts, chondroblasts, smooth muscle, and
retinal pigmented epithelial cells into striated mononucleated myoblasts and
multinucleated myotubes. Proceedings of the National Academy of Sciences of the
United States of America, 87(20), 7988-7992.
Chu, E., & DeVita, V. T. (2006). Physicians' cancer chemotherapy drug manual 2006:
Jones & Bartlett Learning.
Chugun, A., Temma, K., Oyamada, T., Suzuki, N., Kamiya, Y., Hara, Y., Sasaki, T.,
Kondo, H., & Akera, T. (2000). Doxorubicin-induced late cardiotoxicity: delayed
impairment of Ca2+-handling mechanisms in the sarcoplasmic reticulum in the
rat. Canadian Journal of Physiology and Pharmacology, 78(4), 329-338.
Ciccia, A., & Elledge, S. J. (2010). The DNA damage response: making it safe to play
with knives. Molecular Cell, 40(2), 179-204. doi: 10.1016/j.molcel.2010.09.019
Corbi, N., Di Padova, M., De Angelis, R., Bruno, T., Libri, V., Iezzi, S., Floridi, A.,
Fanciulli, M., & Passananti, C. (2002). The α-like RNA polymerase II core
subunit 3 (RPB3) is involved in tissue-specific transcription and muscle
differentiation via interaction with the myogenic factor Myogenin. The
Federation of American Societies for Experimental Biology Journal, 16(12),
1639-1641.
Cornelison, D. D., & Wold, B. J. (1997). Single-cell analysis of regulatory gene
expression in quiescent and activated mouse skeletal muscle satellite cells.
Developmental Biology, 191(2), 270-283. doi: 10.1006/dbio.1997.8721
Cui, H., Schroering, A., & Ding, H.-F. (2002). p53 Mediates DNA Damaging Druginduced Apoptosis through a Caspase-9-dependent Pathway in SH-SY5Y
Neuroblastoma Cells 1 Supported in part by a grant from the Ohio Cancer
Research Associates and Howard Temin Award CA-78534 from the National
Cancer Institute, NIH. 1. Molecular Cancer Therapeutics, 1(9), 679-686.
Davies, K. J., & Doroshow, J. H. (1986). Redox cycling of anthracyclines by cardiac
mitochondria. I. Anthracycline radical formation by NADH dehydrogenase.
Journal of Biological Chemistry, 261(7), 3060-3067.

101

Davis, R. L., Cheng, P. F., Lassar, A. B., & Weintraub, H. (1990). The MyoD DNA
binding domain contains a recognition code for muscle-specific gene activation.
Cell, 60(5), 733-746.
de Melo Gagliato, D., Gonzalez-Angulo, A. M., Lei, X., Theriault, R. L., Giordano, S. H.,
Valero, V., Hortobagyi, G. N., & Chavez-MacGregor, M. (2014). Clinical impact
of delaying initiation of adjuvant chemotherapy in patients with breast cancer.
Journal of Clinical Oncology, JCO. 2013.2049. 7693.
DeAtley, S. M., Aksenov, M. Y., Aksenova, M. V., Harris, B., Hadley, R., Cole Harper,
P., Carney, J. M., & Butterfield, D. A. (1999). Antioxidants protect against
reactive oxygen species associated with adriamycin-treated cardiomyocytes.
Cancer Letters, 136(1), 41-46.
Dedkov, E. I., Kostrominova, T. Y., Borisov, A. B., & Carlson, B. M. (2001). Reparative
myogenesis in long-term denervated skeletal muscles of adult rats results in a
reduction of the satellite cell population. The Anatomical Record, 263(2), 139154.
Dedkov, E. I., Kostrominova, T. Y., Borisov, A. B., & Carlson, B. M. (2003). MyoD and
myogenin protein expression in skeletal muscles of senile rats. Cell and Tissue
Research, 311(3), 401-416.
Dekkers, J. C., van Doornen, L. J., & Kemper, H. C. (1996). The role of antioxidant
vitamins and enzymes in the prevention of exercise-induced muscle damage.
Sports Medicine, 21(3), 213-238.
Dietrich, S., Schubert, F. R., Gruss, P., & Lumsden, A. (1999). The role of the notochord
for epaxial myotome formation in the mouse. Cellular and Molecular Biology
(Noisy-le-grand), 45(5), 601-616.
Dimeo, F., Fetscher, S., Lange, W., Mertelsmann, R., & Keul, J. (1997). Effects of
aerobic exercise on the physical performance and incidence of treatment-related
complications after high-dose chemotherapy. Blood, 90(9), 3390-3394.
Dimeo,F., Rumberger, B.G., & Keul, J. (1998). Aerobic exercise as therapy for cancer
fatigue. Medicine and Science in Sports and Exercise, 30, 475-478.
Doroshow, J. H., & Davies, K. J. (1986). Redox cycling of anthracyclines by cardiac
mitochondria. II. Formation of superoxide anion, hydrogen peroxide, and
hydroxyl radical. Journal of Biolical Chemistry, 261(7), 3068-3074.
Doroshow, J. H., Tallent, C., & Schechter, J. E. (1985). Ultrastructural features of
Adriamycin-induced skeletal and cardiac muscle toxicity. American Journal of
Pathology, 118(2), 288-297.

102

Edmondson, D. G., Cheng, T. C., Cserjesi, P., Chakraborty, T., & Olson, E. N. (1992).
Analysis of the myogenin promoter reveals an indirect pathway for positive
autoregulation mediated by the muscle-specific enhancer factor MEF-2.
Molecular and Cellular Biology, 12(9), 3665-3677.
Evans, W. J. (2004). Protein nutrition, exercise and aging. Journal of the American
College of Nutrition, 23(6 Suppl), 601S-609S.
Favero, T. G., Zable, A. C., & Abramson, J. J. (1995). Hydrogen peroxide stimulates the
Ca2+ release channel from skeletal muscle sarcoplasmic reticulum. Journal of
Biological Chemistry, 270(43), 25557-25563.
Feng Gao, C., Ren, S., Zhang, L., Nakajima, T., Ichinose, S., Hara, T., Koike, K., &
Tsuchida, N. (2001). Caspase-Dependent Cytosolic Release of Cytochrome c and
Membrane Translocation of Bax in p53-Induced Apoptosis. Experimental Cell
Research, 265(1), 145-151.
Fortini, P., Ferretti, C., Pascucci, B., Narciso, L., Pajalunga, D., Puggioni, E. M., Castino,
R., Isidoro, C., Crescenzi, M., & Dogliotti, E. (2012). DNA damage response by
single-strand breaks in terminally differentiated muscle cells and the control of
muscle integrity. Cell Death and Differentiation, 19(11), 1741-1749. doi:
10.1038/cdd.2012.53
Franco, A. A., Odom, R. S., & Rando, T. A. (1999). Regulation of antioxidant enzyme
gene expression in response to oxidative stress and during differentiation of
mouse skeletal muscle. Free Radical Biology and Medicine, 27(9-10), 1122-1132.
Fulda, S., & Debatin, K. M. (2006). Extrinsic versus intrinsic apoptosis pathways in
anticancer chemotherapy. Oncogene, 25(34), 4798-4811. doi:
10.1038/sj.onc.1209608
Gewirtz, D. A. (1999). A critical evaluation of the mechanisms of action proposed for the
antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin.
Biochemical Pharmacology, 57(7), 727-741.
Gilliam, L. A., Ferreira, L. F., Bruton, J. D., Moylan, J. S., Westerblad, H., St Clair, D.
K., & Reid, M. B. (2009). Doxorubicin acts through tumor necrosis factor
receptor subtype 1 to cause dysfunction of murine skeletal muscle. Journal of
Applied Physiology (1985), 107(6), 1935-1942. doi:
10.1152/japplphysiol.00776.2009
Gilliam, L. A., Fisher-Wellman, K. H., Lin, C. T., Maples, J. M., Cathey, B. L., &
Neufer, P. D. (2013). The anticancer agent doxorubicin disrupts mitochondrial
energy metabolism and redox balance in skeletal muscle. Free Radical Biology
and Medicine, 65, 988-996. doi: 10.1016/j.freeradbiomed.2013.08.191

103

Gilliam, L. A., Moylan, J. S., Ann Callahan, L., Sumandea, M. P., & Reid, M. B. (2011).
Doxorubicin causes diaphragm weakness in murine models of cancer
chemotherapy. Muscle and Nerve, 43(1), 94-102.
Gilliam, L. A., Moylan, J. S., Patterson, E. W., Smith, J. D., Wilson, A. S., Rabbani, Z.,
& Reid, M. B. (2012). Doxorubicin acts via mitochondrial ROS to stimulate
catabolism in C2C12 myotubes. American Journal of Physiology - Cell
Physiology, 302(1), C195-202. doi: 10.1152/ajpcell.00217.2011
Gomez-Cabrera, M., Domenech, E., Ji, L., & Viña, J. (2006). Exercise as an antioxidant:
it up-regulates important enzymes for cell adaptations to exercise. Science and
Sports, 21(2), 85-89.
Gomez-Cabrera, M.-C., Domenech, E., & Viña, J. (2008). Moderate exercise is an
antioxidant: upregulation of antioxidant genes by training. Free Radical Biology
and Medicine, 44(2), 126-131.
Gossett, L. A., Kelvin, D. J., Sternberg, E., & Olson, E. N. (1989). A new myocytespecific enhancer-binding factor that recognizes a conserved element associated
with multiple muscle-specific genes. Molecular and Cellular Biology, 9(11),
5022-5033.
Gutierrez, P. L. (2000). The metabolism of quinone-containing alkylating agents: free
radical production and measurement. Frontiers in Bioscience, 5, 629-638.
Haddad, F., & Adams, G. R. (2002). Selected contribution: acute cellular and molecular
responses to resistance exercise. Journal of Applied Physiology (1985), 93(1),
394-403. doi: 10.1152/japplphysiol.01153.2001
Halevy, O., Novitch, B. G., Spicer, D. B., Skapek, S. X., Rhee, J., Hannon, G. J., Beach,
D., & Lassar, A. B. (1995). Correlation of terminal cell cycle arrest of skeletal
muscle with induction of p21 by MyoD. Science, 267(5200), 1018-1021.
Hasty, P., Bradley, A., Morris, J. H., Edmondson, D. G., Venuti, J. M., Olson, E. N., &
Klein, W. H. (1993). Muscle deficiency and neonatal death in mice with a
targeted mutation in the myogenin gene. Nature, 364(6437), 501-506. doi:
10.1038/364501a0
Hauschka, S. (1994). The embryonic origin of muscle. Myology, 1, 3-73.
Hayward, R., Hydock, D., Gibson, N., Greufe, S., Bredahl, E., & Parry, T. (2013). Tissue
retention of doxorubicin and its effects on cardiac, smooth, and skeletal muscle
function. Journal of Physiology and Biochemistry, 69(2), 177-187. doi:
10.1007/s13105-012-0200-0

104
Hayward, R., Lien, C. Y., Jensen, B. T., Hydock, D. S., & Schneider, C. M. (2012).
Exercise training mitigates anthracycline-induced chronic cardiotoxicity in a
juvenile rat model. Pediatric Blood and Cancer, 59(1), 149-154. doi:
10.1002/pbc.23392
Hidalgo, C., Bull, R., Behrens, M. I., & Donoso, P. (2004). Redox regulation of RyRmediated Ca2+ release in muscle and neurons. Biological Research, 37(4), 539552.
Hinterberger, T. J., Sassoon, D. A., Rhodes, S. J., & Konieczny, S. F. (1991). Expression
of the muscle regulatory factor MRF4 during somite and skeletal myofiber
development. Developmental Biology, 147(1), 144-156.
Hool, L. C., Di Maria, C. A., Viola, H. M., & Arthur, P. G. (2005). Role of NAD(P)H
oxidase in the regulation of cardiac L-type Ca2+ channel function during acute
hypoxia. Cardiovascular Research, 67(4), 624-635. doi:
10.1016/j.cardiores.2005.04.025
Hoshi, T., & Lahiri, S. (2004). Cell biology. Oxygen sensing: it's a gas! Science,
306(5704), 2050-2051. doi: 10.1126/science.1107069
Hughes, S. M., Chi, M. M., Lowry, O. H., & Gundersen, K. (1999). Myogenin induces a
shift of enzyme activity from glycolytic to oxidative metabolism in muscles of
transgenic mice. Journal of Cell Biology, 145(3), 633-642.
Hughes, S. M., Koishi, K., Rudnicki, M., & Maggs, A. M. (1997). MyoD protein is
differentially accumulated in fast and slow skeletal muscle fibres and required for
normal fibre type balance in rodents. Mechanisms of Development, 61(1), 151163.
Hughes, S. M., Taylor, J. M., Tapscott, S. J., Gurley, C. M., Carter, W. J., & Peterson, C.
A. (1993). Selective accumulation of MyoD and myogenin mRNAs in fast and
slow adult skeletal muscle is controlled by innervation and hormones.
Development, 118(4), 1137-1147.
Hydock, D. S., Lien, C. Y., Jensen, B. T., Schneider, C. M., & Hayward, R. (2011a).
Characterization of the effect of in vivo doxorubicin treatment on skeletal muscle
function in the rat. Anticancer Research, 31(6), 2023-2028.
Hydock, D. S., Lien, C. Y., Jensen, B. T., Schneider, C. M., & Hayward, R. (2011b).
Exercise preconditioning provides long-term protection against early chronic
doxorubicin cardiotoxicity. Integrative Cancer Therapies, 10(1), 47-57. doi:
10.1177/1534735410392577

105
Ishibashi, J., Perry, R. L., Asakura, A., & Rudnicki, M. A. (2005). MyoD induces
myogenic differentiation through cooperation of its NH2-and COOH-terminal
regions. Journal of Cell Biology, 171(3), 471-482.
Ishido, M., Kami, K., & Masuhara, M. (2004). Localization of MyoD, myogenin and cell
cycle regulatory factors in hypertrophying rat skeletal muscles. Acta Physiologica
Scandinavica, 180(3), 281-289. doi: 10.1046/j.0001-6772.2003.01238.x
Irintchev, A., & Wernig, A. (1987). Muscle damage and repair in voluntarily running
mice: strain and muscle differences. Cell and Tissue Research, 249(3), 509-521.
Ji, L. L., Gomez-Cabrera, M. C., & Vina, J. (2006). Exercise and hormesis: activation of
cellular antioxidant signaling pathway. Annals of the New York Academy of
Sciences, 1067(1), 425-435. doi: 10.1196/annals.1354.061
Kanter, M. M., Hamlin, R. L., Unverferth, D. V., Davis, H. W., & Merola, A. J. (1985).
Effect of exercise training on antioxidant enzymes and cardiotoxicity of
doxorubicin. Journal of Applied Physiology (1985), 59(4), 1298-1303.
Karalaki, M., Fili, S., Philippou, A., & Koutsilieris, M. (2009). Muscle regeneration:
cellular and molecular events. In Vivo, 23(5), 779-796.
Kassar-Duchossoy, L., Gayraud-Morel, B., Gomes, D., Rocancourt, D., Buckingham, M.,
Shinin, V., & Tajbakhsh, S. (2004). Mrf4 determines skeletal muscle identity in
Myf5:Myod double-mutant mice. Nature, 431(7007), 466-471. doi:
10.1038/nature02876
Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B., & Craig, R. W. (1991).
Participation of p53 protein in the cellular response to DNA damage. Cancer
Research, 51(23 Pt 1), 6304-6311.
Kavazis, A. N., Smuder, A. J., & Powers, S. K. (2014). Effects of short-term endurance
exercise training on acute doxorubicin-induced FoxO transcription in cardiac and
skeletal muscle. Journal of Applied Physiology (1985), 117(3), 223-230. doi:
10.1152/japplphysiol.00210.2014
Knobel, H., Loge, J. H., Lund, M. B., Forfang, K., Nome, O., & Kaasa, S. (2001). Late
medical complications and fatigue in Hodgkin’s disease survivors. Journal of
Clinical Oncology, 19(13), 3226-3233.
Kobayashi, J., Antoccia, A., Tauchi, H., Matsuura, S., & Komatsu, K. (2004). NBS1 and
its functional role in the DNA damage response. DNA Repair (Amst), 3(8-9), 855861. doi: 10.1016/j.dnarep.2004.03.023
Kobayashi, J., Tauchi, H., Sakamoto, S., Nakamura, A., Morishima, K.-i., Matsuura, S.,
Kobayashi, T., Tamai, K., Tanimoto, K., & Komatsu, K. (2002). NBS1 Localizes

106
to γ-H2AX Foci through Interaction with the FHA/BRCT Domain. Current
Biology, 12(21), 1846-1851. doi: 10.1016/s0960-9822(02)01259-9
Kosek, D. J., Kim, J. S., Petrella, J. K., Cross, J. M., & Bamman, M. M. (2006). Efficacy
of 3 days/wk resistance training on myofiber hypertrophy and myogenic
mechanisms in young vs. older adults. Journal of Applied Physiology (1985),
101(2), 531-544. doi: 10.1152/japplphysiol.01474.2005
Kurabayashi, M., Jeyaseelan, R., & Kedes, L. (1993). Antineoplastic agent doxorubicin
inhibits myogenic differentiation of C2 myoblasts. Journal of Biological
Chemistry, 268(8), 5524-5529.
Kurabayashi, M., Jeyaseelan, R., & Kedes, L. (1994). Doxorubicin represses the function
of the myogenic helix-loop-helix transcription factor MyoD. Involvement of Id
gene induction. Journal of Biological Chemistry, 269(8), 6031-6039.
L'Ecuyer, T., Sanjeev, S., Thomas, R., Novak, R., Das, L., Campbell, W., & Vander
Heide, R. (2006). DNA damage is an early event in doxorubicin-induced cardiac
myocyte death. American Journal of Physiology - Heart and Circulatory
Physiology, 291(3), H1273-H1280.
Lassar, A. B., Davis, R. L., Wright, W. E., Kadesch, T., Murre, C., Voronova, A.,
Baltimore, D., & Weintraub, H. (1991). Functional activity of myogenic HLH
proteins requires hetero-oligomerization with E12/E47-like proteins in vivo. Cell,
66(2), 305-315. doi: http://dx.doi.org/10.1016/0092-8674(91)90620-E
Lawler, J. M., Powers, S. K., Hammeren, J., & Martin, A. D. (1993). Oxygen cost of
treadmill running in 24-month-old Fischer-344 rats. Medicine and Science in
Sports and Exercise, 25(11), 1259-1264.
Lemercier, C., To, R. Q., Carrasco, R. A., & Konieczny, S. F. (1998). The basic helix–
loop–helix transcription factor Mist1 functions as a transcriptional repressor of
MyoD. The European Molecular Biology Organization Journal, 17(5), 14121422.
Li, Y. P., Chen, Y., Li, A. S., & Reid, M. B. (2003). Hydrogen peroxide stimulates
ubiquitin-conjugating activity and expression of genes for specific E2 and E3
proteins in skeletal muscle myotubes. American Journal of Physiology - Cell
Physiology, 285(4), C806-812. doi: 10.1152/ajpcell.00129.2003
Lin, Q., Schwarz, J., Bucana, C., & Olson, E. N. (1997). Control of mouse cardiac
morphogenesis and myogenesis by transcription factor MEF2C. Science,
276(5317), 1404-1407.
Liu, J., Yeo, H. C., Övervik-Douki, E., Hagen, T., Doniger, S. J., Chu, D. W., Brooks, G.
A., & Ames, B. N. (2000). Chronically and acutely exercised rats: biomarkers of

107
oxidative stress and endogenous antioxidants. Journal of Applied Physiology,
89(1), 21-28. Retrieved from
http://jap.physiology.org/content/jap/89/1/21.full.pdf
Loughna, P. T., & Brownson, C. (1996). Two myogenic regulatory factor transcripts
exhibit muscle-specific responses to disuse and passive stretch in adult rats.
Federation of European Biochemical Societies Letters, 390(3), 304-306.
Lowe, D. A., & Alway, S. E. (1999). Stretch-induced myogenin, MyoD, and MRF4
expression and acute hypertrophy in quail slow-tonic muscle are not dependent
upon satellite cell proliferation. Cell and Tissue Research, 296(3), 531-539.
Lu, J., Webb, R., Richardson, J. A., & Olson, E. N. (1999). MyoR: A muscle-restricted
basic helix–loop–helix transcription factor that antagonizes the actions of MyoD.
Proceedings of the National Academy of Sciences of the United States of America,
96(2), 552-557.
Lyons, G. E., Micales, B. K., Schwarz, J., Martin, J. F., & Olson, E. N. (1995).
Expression of mef2 genes in the mouse central nervous system suggests a role in
neuronal maturation. Journal of Neuroscience, 15(8), 5727-5738.
MacLennan, D. H. (2000). Ca2+ signalling and muscle disease. European Journal of
Biochemistry, 267(17), 5291-5297.
Martin, P. T. (2003). Role of transcription factors in skeletal muscle and the potential for
pharmacological manipulation. Current Opinion in Pharmacology, 3(3), 300-308.
doi: http://dx.doi.org/10.1016/S1471-4892(03)00050-X
McKinnell, I. W., Ishibashi, J., Le Grand, F., Punch, V. G., Addicks, G. C., Greenblatt, J.
F., Dilworth, F. J., & Rudnicki, M. A. (2008). Pax7 activates myogenic genes by
recruitment of a histone methyltransferase complex. Nature Cell Biology, 10(1),
77-84. doi: 10.1038/ncb1671
Mcloon, L. K., Falkenberg, J. H., Dykstra, D., & Iaizzo, P. A. (1998). Doxorubicin
chemomyectomy as a treatment for cervical dystonia: histological assessment
after direct injection into the sternocleidomastoid muscle. Muscle and Nerve,
21(11), 1457-1464.
Megeney, L. A., Kablar, B., Garrett, K., Anderson, J. E., & Rudnicki, M. A. (1996).
MyoD is required for myogenic stem cell function in adult skeletal muscle. Genes
and Development, 10(10), 1173-1183.
Megeney, L. A., & Rudnicki, M. A. (1995). Determination versus differentiation and the
MyoD family of transcription factors. Biochemistry and Cell Biology, 73(9-10),
723-732.

108
Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., & Gianni, L. (2004). Anthracyclines:
molecular advances and pharmacologic developments in antitumor activity and
cardiotoxicity. Pharmacological Reviews, 56(2), 185-229. doi: 10.1124/pr.56.2.6
Molkentin, J. D., Black, B. L., Martin, J. F., & Olson, E. N. (1995). Cooperative
activation of muscle gene expression by MEF2 and myogenic bHLH proteins.
Cell, 83(7), 1125-1136.
Montarras, D., Lindon, C., Pinset, C., & Domeyne, P. (2000). Cultured myf5 null and
myoD null muscle precursor cells display distinct growth defects. Biology of the
Cell, 92(8-9), 565-572.
Moss, F., & Leblond, C. (1971). Satellite cells as the source of nuclei in muscles of
growing rats. The Anatomical Record, 170(4), 421-435.
Müller, I., Jenner, A., Bruchelt, G., Niethammer, D., & Halliwell, B. (1997). Effect of
concentration on the cytotoxic mechanism of doxorubicin—apoptosis and
oxidative DNA damage. Biochemical and Biophysical Research Communications,
230(2), 254-257.
Murre, C., McCaw, P. S., Vaessin, H., Caudy, M., Jan, L. Y., Jan, Y. N., Cabrera, C. V.,
Buskin, J. N., Hauschka, S. D., Lassar, A. B., Weintraub, H., & Baltimore, D.
(1989). Interactions between heterologous helix-loop-helix proteins generate
complexes that bind specifically to a common DNA sequence. Cell, 58(3), 537544.
Nabeshima, Y., Hanaoka, K., Hayasaka, M., Esuml, E., Li, S., Nonaka, I., & Nabeshima,
Y.-i. (1993). Myogenin gene disruption results in perinatal lethality because of
severe muscle defect. Nature, 364(6427), 532-535.
Naidu, P. S., Ludolph, D. C., To, R. Q., Hinterberger, T. J., & Konieczny, S. F. (1995).
Myogenin and MEF2 function synergistically to activate the MRF4 promoter
during myogenesis. Molecular and Cellular Biology, 15(5), 2707-2718.
Naya, F. J., & Olson, E. (1999). MEF2: a transcriptional target for signaling pathways
controlling skeletal muscle growth and differentiation. Current Opinion in Cell
Biology, 11(6), 683-688.
Nelson, W. G., & Kastan, M. B. (1994). DNA strand breaks: the DNA template
alterations that trigger p53-dependent DNA damage response pathways.
Molecular and Cellular Biology, 14(3), 1815-1823.
Neville, C. M., Schmidt, M., & Schmidt, J. (1992). Response of myogenic determination
factors to cessation and resumption of electrical activity in skeletal muscle: a
possible role for myogenin in denervation supersensitivity. Cellular and
Molecular Neurobiology, 12(6), 511-527.

109

Olson, E., Arnold, H.-H., Rigby, P., & Wold, B. (1996). Know Your Neighbors: Three
Phenotypes in Null Mutants of the Myogenic bHLH Gene MRF4. Cell, 85(1), 1-4.
Olson, E. N., Perry, M., & Schulz, R. A. (1995). Regulation of muscle differentiation by
the MEF2 family of MADS box transcription factors. Developmental Biology,
172(1), 2-14. doi: 10.1006/dbio.1995.0002
Pallafacchina, G., François, S., Regnault, B., Czarny, B., Dive, V., Cumano, A.,
Montarras, D., & Buckingham, M. (2010). An adult tissue-specific stem cell in its
niche: A gene profiling analysis of in vivo quiescent and activated muscle
satellite cells. Stem Cell Research, 4(2), 77-91.
Primeau, A. J., Adhihetty, P. J., & Hood, D. A. (2002). Apoptosis in heart and skeletal
muscle. Canadian Journal of Applied Physiology, 27(4), 349-395.
Psilander, N., Damsgaard, R., & Pilegaard, H. (2003). Resistance exercise alters MRF
and IGF-I mRNA content in human skeletal muscle. Journal of Applied
Physiology (1985), 95(3), 1038-1044. doi: 10.1152/japplphysiol.00903.2002
Puri, P. L., Bhakta, K., Wood, L. D., Costanzo, A., Zhu, J., & Wang, J. Y. (2002). A
myogenic differentiation checkpoint activated by genotoxic stress. Nature
Genetics, 32(4), 585-593. doi: 10.1038/ng1023
Puri, P. L., Medaglia, S., Cimino, L., Maselli, C., Germani, A., De Marzio, E., Levrero,
M., & Balsano, C. (1997). Uncoupling of p21 induction and MyoD activation
results in the failure of irreversible cell cycle arrest in doxorubicin-treated
myocytes. Journal of Cellular Biochemistry, 66(1), 27-36.
Radak, Z., Chung, H. Y., & Goto, S. (2008). Systemic adaptation to oxidative challenge
induced by regular exercise. Free Radical Biology and Medicine, 44(2), 153-159.
doi: 10.1016/j.freeradbiomed.2007.01.029
Radak, Z., Chung, H. Y., Koltai, E., Taylor, A. W., & Goto, S. (2008). Exercise,
oxidative stress and hormesis. Ageing Research Reviews, 7(1), 34-42. doi:
10.1016/j.arr.2007.04.004
Rapozzi, V., Comelli, M., Mavelli, I., Sentjurc, M., Schara, M., Perissin, L., & Giraldi, T.
(1998). Melatonin and oxidative damage in mice liver induced by the prooxidant
antitumor drug, adriamycin. In Vivo (Athens, Greece), 13(1), 45-50.
Raue, U., Slivka, D., Jemiolo, B., Hollon, C., & Trappe, S. (2006). Myogenic gene
expression at rest and after a bout of resistance exercise in young (18–30 yr) and
old (80–89 yr) women. Journal of Applied Physiology, 101(1), 53-59.

110
Rawls, A., Valdez, M. R., Zhang, W., Richardson, J., Klein, W. H., & Olson, E. N.
(1998). Overlapping functions of the myogenic bHLH genes MRF4 and MyoD
revealed in double mutant mice. Development, 125(13), 2349-2358.
Relaix, F., Rocancourt, D., Mansouri, A., & Buckingham, M. (2004). Divergent functions
of murine Pax3 and Pax7 in limb muscle development. Genes and Development,
18(9), 1088-1105. doi: 10.1101/gad.301004
Rudnicki, M., Le Grand, F., McKinnell, I., & Kuang, S. (2008). The molecular regulation
of muscle stem cell function. Paper presented at the Cold Spring Harbor symposia
on quantitative biology.
Rudnicki, M. A., Braun, T., Hinuma, S., & Jaenisch, R. (1992). Inactivation of MyoD in
mice leads to up-regulation of the myogenic HLH gene Myf-5 and results in
apparently normal muscle development. Cell, 71(3), 383-390.
Rudnicki, M. A., Schnegelsberg, P. N., Stead, R. H., Braun, T., Arnold, H.-H., &
Jaenisch, R. (1993). MyoD or Myf-5 is required for the formation of skeletal
muscle. Cell, 75(7), 1351-1359.
Ruzinova, M. B., & Benezra, R. (2003). Id proteins in development, cell cycle and
cancer. Trends in Cell Biology, 13(8), 410-418. doi:
http://dx.doi.org/10.1016/S0962-8924(03)00147-8
Sabourin, L. A., Girgis-Gabardo, A., Seale, P., Asakura, A., & Rudnicki, M. A. (1999).
Reduced differentiation potential of primary MyoD−/− myogenic cells derived
from adult skeletal muscle. Journal of Cell Biology, 144(4), 631-643.
Sabourin, L. A., & Rudnicki, M. A. (2000). The molecular regulation of myogenesis.
Clinical Genetics, 57(1), 16-25.
Sakuma, K., Watanabe, K., Sano, M., Uramoto, I., Sakamoto, K., & Totsuka, T. (1999).
The adaptive response of MyoD family proteins in overloaded, regenerating and
denervated rat muscles. Biochimica et Biophysica Acta, 1428(2-3), 284-292.
Schiaffino, S., Bormioli, S. P., & Aloisi, M. (1976). The fate of newly formed satellite
cells during compensatory muscle hypertrophy. Virchows Archive B - Cell
Pathology, 21(2), 113-118.
Seale, P., Sabourin, L. A., Girgis-Gabardo, A., Mansouri, A., Gruss, P., & Rudnicki, M.
A. (2000). Pax7 is required for the specification of myogenic satellite cells. Cell,
102(6), 777-786.
Simonatto, M., Giordani, L., Marullo, F., Minetti, G. C., Puri, P. L., & Latella, L. (2011).
Coordination of cell cycle, DNA repair and muscle gene expression in myoblasts
exposed to genotoxic stress. Cell Cycle, 10(14), 2355-2363.

111

Simonatto, M., Marullo, F., Chiacchiera, F., Musaro, A., Wang, J. Y., Latella, L., & Puri,
P. L. (2013). DNA damage-activated ABL-MyoD signaling contributes to DNA
repair in skeletal myoblasts. Cell Death and Differentiation, 20(12), 1664-1674.
doi: 10.1038/cdd.2013.118
Singal, P., Li, T., Kumar, D., Danelisen, I., & Iliskovic, N. (2000). Adriamycin-induced
heart failure: mechanisms and modulation. Molecular and Cellular Biochemistry,
207(1-2), 77-86.
Singal, P. K., & Iliskovic, N. (1998). Doxorubicin-induced cardiomyopathy. New
England Journal of Medicine, 339(13), 900-905. doi:
10.1056/NEJM199809243391307
Siu, P. M., Donley, D. A., Bryner, R. W., & Alway, S. E. (2003). Citrate synthase
expression and enzyme activity after endurance training in cardiac and skeletal
muscles. Journal of Applied Physiology (1985), 94(2), 555-560. doi:
10.1152/japplphysiol.00821.2002
Siu, P. M., Donley, D. A., Bryner, R. W., & Alway, S. E. (2004). Myogenin and
oxidative enzyme gene expression levels are elevated in rat soleus muscles after
endurance training. Journal of Applied Physiology (1985), 97(1), 277-285. doi:
10.1152/japplphysiol.00534.2003
Smith, C. K., 2nd, Janney, M. J., & Allen, R. E. (1994). Temporal expression of
myogenic regulatory genes during activation, proliferation, and differentiation of
rat skeletal muscle satellite cells. Journal of Cellular Physiology, 159(2), 379385. doi: 10.1002/jcp.1041590222
Smith, P. K., Krohn, R. I., Hermanson, G. T., Mallia, A. K., Gartner, F. H., Provenzano,
M. D., Fujimoto, E. K., Goeke, N. M., Olson, B. J., & Klenk, D. C. (1985).
Measurement of protein using bicinchoninic acid. Analytical Biochemistry,
150(1), 76-85. doi: http://dx.doi.org/10.1016/0003-2697(85)90442-7
Smuder, A. J., Kavazis, A. N., Min, K., & Powers, S. K. (2011a). Exercise protects
against doxorubicin-induced markers of autophagy signaling in skeletal muscle.
Journal of Applied Physiology (1985), 111(4), 1190-1198. doi:
10.1152/japplphysiol.00429.2011
Smuder, A. J., Kavazis, A. N., Min, K., & Powers, S. K. (2011b). Exercise protects
against doxorubicin-induced oxidative stress and proteolysis in skeletal muscle.
Journal of Applied Physiology (1985), 110(4), 935-942. doi:
10.1152/japplphysiol.00677.2010

112
Spicer, D. B., Rhee, J., Cheung, W. L., & Lassar, A. B. (1996). Inhibition of myogenic
bHLH and MEF2 transcription factors by the bHLH protein Twist. Science,
272(5267), 1476-1480.
Stathopoulos, G., Malamos, N., Dontas, I., Deliconstantinos, G., Perrea-Kotsareli, D., &
Karayannacos, P. (1997). Inhibition of adriamycin cardiotoxicity by 5fluorouracil: a potential free oxygen radical scavenger. Anticancer Research,
18(6A), 4387-4392.
Stone, P., Hardy, J., Broadley, K., Tookman, A. J., Kurowska, A., & A'Hern, R. (1999).
Fatigue in advanced cancer: a prospective controlled cross-sectional study. British
Journal of Cancer, 79(9-10), 1479-1486. doi: 10.1038/sj.bjc.6690236
Sugarbaker, P. H. (2009). Cytoreductive surgery and perioperative intraperitoneal
chemotherapy for the treatment of advanced primary and recurrent ovarian
cancer. Current Opinion in Obstetrics and Gynecology, 21(1), 15-24. doi:
10.1097/GCO.0b013e32831f8f32
Sun, X. H., Copeland, N. G., Jenkins, N. A., & Baltimore, D. (1991). Id proteins Id1 and
Id2 selectively inhibit DNA binding by one class of helix-loop-helix proteins.
Molecular and Cellular Biology, 11(11), 5603-5611.
Swift, L. P., Rephaeli, A., Nudelman, A., Phillips, D. R., & Cutts, S. M. (2006).
Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell
death. Cancer Research, 66(9), 4863-4871. doi: 10.1158/0008-5472.CAN-053410
Tajbakhsh, S., Rocancourt, D., Cossu, G., & Buckingham, M. (1997). Redefining the
genetic hierarchies controlling skeletal myogenesis: Pax-3 and Myf-5 act
upstream of MyoD. Cell, 89(1), 127-138.
Tang, X. D., Santarelli, L. C., Heinemann, S. H., & Hoshi, T. (2004). Metabolic
regulation of potassium channels. Annual Review of Physiology, 66, 131-159. doi:
10.1146/annurev.physiol.66.041002.142720
Tewey, K. M., Rowe, T. C., Yang, L., Halligan, B. D., & Liu, L. F. (1984). Adriamycininduced DNA damage mediated by mammalian DNA topoisomerase II. Science,
226(4673), 466-468.
Tisdale, M. J. (2009). Mechanisms of cancer cachexia. Physiological Reviews, 89(2),
381-410. doi: 10.1152/physrev.00016.2008
Ustanina, S., Carvajal, J., Rigby, P., & Braun, T. (2007). The myogenic factor Myf5
supports efficient skeletal muscle regeneration by enabling transient myoblast
amplification. Stem Cells, 25(8), 2006-2016. doi:10.1634/stemcells.2006-0736

113
Valko, M., Leibfritz, D., Moncol, J., Cronin, M. T., Mazur, M., & Telser, J. (2007). Free
radicals and antioxidants in normal physiological functions and human disease.
International Journal of Biochemistry and Cell Biology, 39(1), 44-84. doi:
10.1016/j.biocel.2006.07.001
Van der Speeten, K., Stuart, O. A., Mahteme, H., & Sugarbaker, P. H. (2009). A
pharmacologic analysis of intraoperative intracavitary cancer chemotherapy with
doxorubicin. Cancer Chemotherapy and Pharmacology, 63(5), 799-805. doi:
10.1007/s00280-008-0800-0
van Norren, K., van Helvoort, A., Argiles, J. M., van Tuijl, S., Arts, K., Gorselink, M., . .
. van der Beek, E. M. (2009). Direct effects of doxorubicin on skeletal muscle
contribute to fatigue. British Journal of Cancer, 100(2), 311-314. doi:
10.1038/sj.bjc.6604858
Van Remmen, H., Hamilton, M. L., & Richardson, A. (2003). Oxidative damage to DNA
and aging. Exercise and Sport Sciences Reviews, 31(3), 149-153.
Venuti, J. M., Morris, J. H., Vivian, J. L., Olson, E. N., & Klein, W. H. (1995). Myogenin
is required for late but not early aspects of myogenesis during mouse
development. Journal of Cell Biology, 128(4), 563-576.
Vivian, J. L., Olson, E. N., & Klein, W. H. (2000). Thoracic skeletal defects in
myogenin-and MRF4-deficient mice correlate with early defects in myotome and
intercostal musculature. Developmental Biology, 224(1), 29-41.
Voytik, S. L., Przyborski, M., Badylak, S. F., & Konieczny, S. F. (1993). Differential
expression of muscle regulatory factor genes in normal and denervated adult rat
hindlimb muscles. Developmental Dynamics, 198(3), 214-224.
Walters, E. H., Stickland, N. C., & Loughna, P. T. (2000). The expression of the
myogenic regulatory factors in denervated and normal muscles of different
phenotypes. Journal of Muscle Research and Cell Motility, 21(7), 647-653.
Wang, J., & Conboy, I. (2010). Embryonic vs. adult myogenesis: challenging the
‘regeneration recapitulates development’paradigm. Journal of Molecular Cell
Biology, 2(1), 1-4.
Weintraub, H. (1993). The MyoD family and myogenesis: redundancy, networks, and
thresholds. Cell, 75(7), 1241-1244.
Williamson, D. L., Godard, M. P., Porter, D. A., Costill, D. L., & Trappe, S. W. (2000).
Progressive resistance training reduces myosin heavy chain coexpression in single
muscle fibers from older men. Journal of Applied Physiology (1985), 88(2), 627633.

114
Wonders, K. Y., Hydock, D. S., Schneider, C. M., & Hayward, R. (2008). Acute exercise
protects against doxorubicin cardiotoxicity. Integrative Cancer Therapies, 7(3),
147-154.
Wonders, K. Y., Hydock, D. S., Schneider, C. M., & Hayward, R. (2008). Acute exercise
protects against doxorubicin cardiotoxicity. Integratvie Cancer Therapies, 7(3),
147-154. doi: 10.1177/1534735408322848
Yang, Y., Creer, A., Jemiolo, B., & Trappe, S. (2005). Time course of myogenic and
metabolic gene expression in response to acute exercise in human skeletal muscle.
Journal of Applied Physiology (1985), 98(5), 1745-1752. doi:
10.1152/japplphysiol.01185.2004
Yutzey, K. E., Rhodes, S. J., & Konieczny, S. F. (1990). Differential trans activation
associated with the muscle regulatory factors MyoD1, myogenin, and MRF4.
Molecular and Cellular Biology, 10(8), 3934-3944.
Zammit, P., & Beauchamp, J. (2001). The skeletal muscle satellite cell: stem cell or son
of stem cell? Differentiation, 68(4-5), 193-204.
Zammit, P. S., Golding, J. P., Nagata, Y., Hudon, V., Partridge, T. A., & Beauchamp, J.
R. (2004). Muscle satellite cells adopt divergent fates: a mechanism for selfrenewal? Journal of Cell Biology, 166(3), 347-357. doi: 10.1083/jcb.200312007
Zhou, Z., & Bornemann, A. (2001). MRF4 protein expression in regenerating rat muscle.
Journal of Muscle Research and Cell Motility, 22(4), 311-316. Retrieved from
http://www.ncbi.nlm.nih.gov/pubmed/11808771
Zhu, Z., & Miller, J. B. (1997). MRF4 can substitute for myogenin during early stages of
myogenesis. Developmental Dynamics, 209(2), 233-241. doi:
10.1002/(SICI)1097-0177(199706)209:2<233::AID-AJA9>3.0.CO;2-J
Zorzato, F., Salviati, G., Facchinetti, T., & Volpe, P. (1985). Doxorubicin induces
calcium release from terminal cisternae of skeletal muscle. A study on isolated
sarcoplasmic reticulum and chemically skinned fibers. Journal of Biological
Chemistry, 260(12), 7349-7355.
Zweigerdt, R., Braun, T., & Arnold, H.-H. (1997). Faithful expression of the Myf-5 gene
during mouse myogenesis requires distant control regions: a transgene approach
using yeast artificial chromosomes. Developmental Biology, 192(1), 172-180.

115

APPENDIX A
UNIVERSITY OF NORTHERN COLORADO
INSTITUTIONAL ANIMAL CARE
AND USE COMMITTEE

116

IACUC Memorandum

To:

Dr. David Hydock

From: Laura Martin, Director of Compliance and Operations
CC:

IACUC Files

Date:

8/26/2014

Re:

IACUC Protocol 1407C-DH-R-17 Approval

The UNC IACUC has completed a final review of your protocol “Nutrition and Exercise in
Cancer Treatment-Induced Muscle Dysfunction”. The protocol review was based on the
requirements of Government Principles for the Utilization and Care of Vertebrate Animals Used
in Testing, Research, and Training; the Public Health Policy on Humane Care and Use of
Laboratory Animals; and the USDA Animal Welfare Act and Regulations. Based on the review,
the IACUC has determined that all review criteria have been adequately addressed. The PI/PD
is approved to perform the experiments or procedures as described in the identified protocol as
submitted to the Committee. This protocol has been assigned the following number 1407C-DHR-17.
The next annual review will be due before August 26, 2015.
Sincerely,

___________________________________________
Laura Martin, Director of Compliance and Operations
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Pilot Study
Tissue samples of SED-SAL (6) and SED-DOX (6) Sprague-Dawley rats, which
received injection 5 days prior to sacrifice, were analyzed with Western blot and ECL
imaging techniques (Figure 1). Compared to SAL-treated animals, the DOX-treated
group exhibited significantly higher levels of Mrf4 and myogenin in the SOL. A trend for
decreased Myf5 and MyoD1 expression in the SOL was also observed. The EDL of
DOX-treated animals exhibited increased levels of Myf5 and MyoD1 and decreased
expression of Mrf4 just above significance.

Upon examination of the same hindlimb skeletal muscle tissues of SpragueDawley rats 3 days after injections (Figure 2), Myf5 protein levels appear to be much
greater in the fast-twitch EDL. When examining Mrf4 levels, bands appear darker in
slow, oxidative SOL. These samples were not run with a housekeeping protein to ensure
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protein concentrations of samples were uniform. However, protein samples loaded in
pilot study were at a concentration of 15 µg. Increased concentrated protein loading will
likely elicit higher detection of MRFs. Dedkov and colleagues (2003) effectively
identified MyoD and myogenin proteins with Western blot with similar sample
concentration (50 µg per lane).

As stated in previous research, a differential expression of MRF proteins exists
between fibers types, and may play a role in determining phenotypes. Additionally, DOX
appears to alter levels in SED animals. Both resistance and run exercise has been shown
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to elevate MRF mRNA levels, but these transcripts return to basal conditions 24 hours
following single bouts (Psilander et al., 2003; Yang et al., 2005). Given functional MRF
proteins are expressed after mRNA, their presence should be apparent in periods
following mRNA expression. However, as shown in denervation studies, mRNA levels
may increase without satellite cell activation and no change in muscle mass (Dedkov,
Kostrominova, Borisov, & Carlson, 2001; Sakuma et al., 1999; Voytik et al., 1993;
Walters, Stickland, & Loughna, 2000). To avoid adaptation to training and return to basal
levels of Myf5 and Myod, a 2-week training period will be employed.
Investigating the effects of endurance exercise and DOX treatment on MRF
protein expression may provide insight to mechanisms potentially preserving skeletal
muscle adaptation and regenerative capacity. This proposed research is a practical study
based on supported translational research that can be implemented fairly easily to
improve health and well-being in an already at-risk patient population.

